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The hypothalamic hormones, thyrotrophin-releasing hormone (TRH) and 
gonadotrophin-releasing hormone (GnRH), play pivotal roles in the growth and sexual 
maturation of chickens. In chickens, TRH regulates the release and synthesis of 
thyrotrophin (TSH) and also acts as a growth hormone-releasing factor. GnRH stimulates 
the release and synthesis of gonadotrophins (LH and FSH). 
TRH and GnRH are released and stored in the median eminence, and both 
hormones are transported into the pituitary gland via the hypophysial portal circulation. 
TRH and GnRH exert their physiological functions by binding to their specific receptors 
(TRH receptor and GnRH receptor, respectively) on the surface of cells in the pituitary 
gland. The activated receptors couple to guanine nucleotide-binding regulatory proteins (G 
proteins), Gq and/or G11, which in turn triggers the . secondary messenger [1,2-
diacylglycerol (DAG) and inositoltrisphosphate (IP3)] signalling cascade. The signalling 
generates the physiological effects of the hormones. The TRH-R and GnRH-R are 
members of G-protein coupled receptor (GPCR) family. · 
The objective of this thesis was to clone and characterise the chicken TRH and 
GnRH receptors as useful tools for investigating the regulatory roles of TRH and GnRH 
receptors in the growth and sexual maturation of chickens. In addition, sequence 
information of the receptors would potentially assist in elucidating the binding sites and the 
molecular nature of the processes involved in receptor activation. 
Although the TRH and GnRH receptors have been cloned from several mammalian 
species, none had been cloned from non-mammalian vertebrates at the commencement of 
this study. In view of the difficulties of cloning these receptors, a combined strategy has 
been used to clone the TRH and GnRH receptors from the chicken pituitary gland. The 
chicken TRH receptor cDNAs have been cloned from a pituitary cDNA library, using the 
mouse TRH receptor, and a partial gene of the chicken TRH receptor, as probes. However, 
they are all incomplete cDNA clones. Consequentially, PCR has been applied to amplify 
the full-length chicken TRH receptor. Various "mutated" sequences (differences in the 
sequences of the cDNA clones isolated from a cDNA library) were noted in the full-length 
clone. Therefore, a ''wild-type" chicken TRH receptor has been constructed. On the 
other hand, the chicken GnRH receptor cDNA could not be isolated from the cDNA 
libraries, constructed from intact or castrated chicken pituitary glands, either by using a 
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partial gene of the chicken GnRH receptor, or the mouse GnRH receptor cDNA as a probe. 
A combined strategy (including PCR 5' -RACE, and screening of a chicken genomic 
library) has been applied to obtain the 5'un-translated and 3'un-translated regions of the 
chicken GnRH receptor from the chicken pituitary cDNA and genomic DNAs, 
respectively. The sequence data of both regions has been used to design two pairs of nested 
primers, which flank an entire open reading frame. A full-length chicken GnRH receptor 
has been amplified by PCR with two pairs of the nested primers. However, the PCR 
application fails to amplify up ''wild type" sequences from the receptor gene. Therefore, a 
''wild type" chicken GnRH receptor was constructed. 
The chicken TRH receptor shares over 80 % identity of amino acid sequences with 
mammalian TRH receptors. The putative binding sites of the mammalian TRH receptor, 
Tyr106, Asn110, Tyr282, and Arg306, are all conserved in the chicken receptor. 
Pharmacological studies employing several TRH analogs reveal that there are no 
significant differences between the chicken and mouse TRH receptors on ligand binding 
and inositol phosphate production. Several truncated chicken TRH receptors have been 
isolated from a chicken pituitary cDNA library. They contain a stop codon (TAA} in the 
putative third intracellular loop. The 20 amino acids that precede the stop codon in these 
clones have no homology with the mammalian counterpart. The divergent region has been 
verified as an intron by southern blot and PCR analysis. 
The chicken GnRH receptor comprises several unique features, compared to the 
mammalian GnRH receptor. The chicken GnRH receptor contains a longer N-terminus, a 
strikingly short intracellular loop 1, and an intracellular C-terminal tail that is absent in the 
mammalian GnRH receptor. Additionally, the chicken receptor possesses two Asp (D) 
residues in TM 2 and TM 7 (DID), whereas Asn (N) and Asp residues present in these 
domains in mammal receptors and DIN in the majority of GPCRs. The amino acid 
sequences of the chicken GnRH receptor shows only about 40 % identity to those of the 
mammalian homologues. However, the putative binding sites Asn102, Lys
121
, and Glu301 , 
which have been proposed in the mouse GnRH receptor, are all conserved in the chicken 
GnRH receptor. Intriguingly, the chicken GnRH receptor exhibits distinct pharmacological 
properties. For example, the chicken GnRH receptor displays higher affinity for chicken 
GnRH II analogues than for mammalian GnRH or chicken GnRH I, while the mammalian 
receptor favours mammalian GnRH. Although several mammalian antagonists behaved as 
pure antagonists in their interaction with the chicken receptor, 
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three mammalian GnRH antagonists generated an agonistic effect to the chicken 
receptor. This feature was apparently due to the presence of a D-Lys residue in position 
6 of these analogues. 
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1 INTRODUCTION 
The growth and sexual maturation of chickens is controlled by an intricate 
mechanism which involves endocrine, paracrine and autocrine factors. Growth hormone 
(GH), thyroid hormones (T3 and T4), and sex hormones (testosterone, estradiol, and 
progesterone) are three major classes of factors involved in the mechanism (Scanes, et 
al.,1990). These hormones are controlled and regulated by hypothalamic hormones, 
thyrotrophin-releasing hormone (TRH) and gonadotrophin-releasing hormone (GnRH), and 
are also regulated by the interactive network between systems of the thyroid and the gonad. 
It is well established that TRH and GnRH initiate their physiological functions by 
interacting with their specific receptors (i.e. TRH-R and GnRH-R) on the surfaces of cells 
and that these receptors couple to guanine nucleotide-binding regulatory proteins (G 
proteins) (Hinkle, 1989; review Sealfon et al., 1997) which in turn trigger the signalling 
cascades. The signalling promotes the biological effects of the hormones. This study has 
been undertaken to clone and pharmacologically characterise the TRH and GnRH 
receptors. The cloned receptors will provide useful tools to unveil the molecular basis of 
action of the TRH and GnRH in avian growth and sexual maturation. Furthermore, the 
amino acid sequences of the receptors will give an insight into the structural conformation 
and molecular functioning of the TRH and GnRH receptors. 
The present chapter will briefly explain the physiological roles of GH and 
gonadotrophins in the growth and maturation of the chicken. This will be followed by a 
discussion of the physiological functions of TRH and GnRH on regulating GH and 
· gonadotrophin release. Finally, the structure and function of the TRH and GnRH receptors 
will be considered. 
The growth and sexual maturation of chickens are under complex hormonal control. 
GH is the most important hormone in the control of growth in poultry (Scanes and 
Lauterio, 1984; Scanes et al., 1990). In physiological conditions, plasma concentrations of 
GH are first detectable on day 17 of chicken embryonic development, and increase during 
the week following hatching. The concentrations of GH are high between 1 to 8 weeks of 
age. Thereafter, the concentrations decline to reach a low, relatively stable level prior to 
puberty (Scanes et al., 1990). In addition, before the end of the rapid growth phase, 
concentrations of plasma gonadotrophins begin to increase slowly, reaching maximum 
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values at the onset of puberty, between 17-21 weeks of age. In puberty, GH regulates 
gonadal functions in birds, by means of the somatomedins' actions on ovarian follicular 
development. The release of somatomedins is stimulated by GH from liver. They exhibit 
an action on the proliferation of granulosa and theca cells, and inhibit LH-induced 
aromatase activity in the theca cells (Pecfdie et al., 1993). Somatomedins increase basal 
progesterone production and enhances LH-stimulated progesterone production (Peddie et 
al., 1993). During the follicular growth period of the hen, in addition to accumulation of 
yolk, the number of granulosa and theca cells also increases rapidly (Etches et al., 1983). 
There are different productions of steroid hormones by the follicles. For example, a 
dramatic increase in basal and LH stimulated progesterone production (Hammond et al., 
1981 ), a marked reduction in progesterone metabolism to androstenedione by theca cells 
(Marrone and Hertelendy, 1985), and a decline in aromatase activity in theca cells, 48 h 
before ovulation (Armstrong, 1984). 
GH secretion is under the control of both stimulatory and inhibitory hypothalamo-
hypophysiotropic factors in mammals and birds. These factors are released from nerve 
terminals of the median eminence into the anterior pituitary gland via the hypophyseal 
portal circulation. The system in birds seems to differ from that of mammals. In birds, the 
factors involved in GH secretion are TRH (stimulatory), growth hormone-releasing factors 
(GRF, stimulatory), and somatostatin (SRIF, inhibitory) (Scanes and Lauterio, 1984). TRH 
is more potent than human GRF in increasing plasma concentrations of GH in chicken in 
vivo and in vitro (Harvey et al., 1984; 1985), whereas, in mammals, TRH shows 
contradictory results (stimulation or inhibition) on the synthesis of GH in physiologi~al 
condition (see review Harvey 1990a). The differential role of TRH in chicken may further 
be elucidated by intricate interactions between the hypothalamo-pituitary-thyroid axis and 
GH. In chicken, GH stimulates the conversion of thyroxine (T4 ) to tri-iodothyronine (T3 ) 
by enhancing hepatic monodeiodinase activity (Kuhn et al., 1987), but suppresses thyroidal 
iodide uptake (Chandola and Thapliyal, 1992). Conversely, T3 depresses plasma 
concentrations of GH (Harvey, 1983), attenuates the TRH-induced peak of GH in a dose-
dependent manner (Tixier-Boichard et al., 1991), and inhibits both TRH- and GRF-induced 
GH release from pituitary tissue in vitro (Scanes and Harvey, 1989). Taken together, TRH 
acts as a growth hormone-releasing factor in the chicken. 
3 
In sexual maturation of the chicken, it has been well established that the 
hypothalamic peptide, GnRH, plays a pivotal role in the hypothalamo-pituitary-gonad 
reproductive axis. The pulsatile secretion of GnRH stimulates luteinising hormone (LH) 
and follicle-stimulating hormone (FSH) release from the pituitary gland in a pulsatile 
manner, which in turn regulates gonadal functions. Interestingly, there is evidence 
indicating that gonadal conditions affect the pituitary-thyroid system. The plasma 
concentrations of TSH and T4 are significantly decreased in orchidectomised rats (Chen 
and Walfish, 1978). On the other hand, the concentrations of TRH and TRH-Gly (a 
precursor) in the posterior pituitary gland increase significantly with orchidectomy, and are 
returned to the normal range by testosterone replacement (Pekary et al., 1990). 
Furthermore, TRH in the posterior pituitary gland is increased by 25 % in the castrated rat, 
but shows no effect on the level of TRH-Gly mRNA in the hypothalamus (Rondeel et al., 
1995). 
The isolation and synthesis of TRH and GnRH over 2 decades ago (B0ler et al. 
1969; Burgus et al., 1969; Matsuo et al., 1971; Burgus et al., 1972), lead to the 
understanding of their distribution and biological functions. Both peptides are ubiquitous in 
the hypothalamus and in extra-hypothalamic regions, and exert biological roles as 
hormones, neurotransmitters, and neuromodulators. 
1.1 Distribution and physiological roles of TRH and GnRH 
TRH was the first hypophysiotrophic peptide to be isolated from pig hypothalamus 
and is a tripeptide consisting of pGlu-His-Pro-NH2 (Burgus et al., 1969; Beier et al., 1969). 
The structure of TRH is identical in all vertebrates classes and is active in all mammals, 
birds and amphibians. Structure-function activity studies of a large number of analogues 
have demonstrated that the side chains of all three amino acid residues of TRH are 
involved in receptor binding (Vale et al., 1973; Gershengom et al., 1996)). 
Distribution : It has been postulated that the TRH-producing cells are derivatives 
of the embryonic neuroectodei:m in vertebrates. Immunoreactive (ir)-TRH neurons are 
present in many regions of the hypothalamus, extending from rostral portions of the 
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preoptic nucleus to the mammillary complex (Leehan and Jackson, 1982). Regions include 
the paraventricular nucleus, the dorsal and ventral portions of the dorsomedial nucleus, the 
arcuate nucleus, the perifomical region, the periventricular nucleus throughout the extent of 
the third ventricle, the median eminence, the dorsal and ventral premammillary nuclei. The 
ir-TRH neurones are also found in extra-hypothalamic regions of the brain (including the 
medulla, the cerebrum, the cerebellum, and the spinal cord) and gastrointestinal tissues 
(including the pancreas, the stomach, the duodenum, and the colon) (Leppaluoto et al., 
1978). TRH has also been isolated from frog skin and retina (Jackson and Reichlin, 1977). 
The wide distribution of TRH in and outside of the CNS reflects the diversity of its 
physiological roles. 
Physiological roles : TRH is released by neurones in the hypothalamus and is 
stored in the median eminence. It is transported to the pituitary gland by the hypophyseal 
portal circulation. TRH displays different physiological functions on different cell types of 
the pituitary gland in different vertebrates. TRH stimulates the biosynthesis and release of 
thyrotrophin (TSH) from thyrotrophs in the mammals and aves, but has no effect on TSH 
release in the amphibian (Nelson, 1982). It also stimulates prolactin release from 
lactotrophs in most mammals and aves (Fink et al., 1983; Shimada et al., 1991). It has 
been shown that TRH plays an important role in increasing the transcription of prolactin 
mRNA in the chicken. The prolactin is responsible for the behaviours of incubation and 
brooding in hens (Shimada et al., 1991; Zadwomy et al., 1989). 
An important physiological role of TRH is to stimulate OH release from 
somatotrophs in the pituitary in birds (see review, Harvey 1990a). TRH and its analogues 
rapidly (within 5 min) increase OH release from somatotrophs in vivo and in vitro in 
chickens, turkeys, pigeons, and ducks. The activity of TRH on stimulating OH release is 
more potent than that of mammalian ORF preparations in chickens (Harvey et al., 1984). It 
has been suggested that TRH and ORF exerted synergistic effects on OH release (Perez et 
al., 1989), indicating that the pathway of TRH-induced OH release differs from that of the 
ORF effect. The physiological function of TRH in OH regulation is inhibited by SRIF in 
vivo (Harvey and Scanes, 1987) and in vitro (Leung and Taylor, 1983). Moreover, thyroid 
hormone may provide a negative feedback pathway in the control of TRH-induced OH 
secretion (Harvey, 1990b ). In addition to its hypophysiotropic effects, TRH has roles in 
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neurotransmission, neuromodulation, and peripheral hormone actions m vertebrates 
(Metcalf and Jackson , 1989). 
GnRH 





Gly10 amide) was first purified from the hypothalami of pigs (Matsuo et al. , 1971) and 
sheep (Burgus et al., 1972). To date, ten additional isoforms of GnRH have been isolated 
from other vertebrates and protochordates: chicken GnRH I ( cGnRH I, King and Millar, 
1982; Miyamoto et al., 1982), salmon GnRH (Sherwood et al., 1983), chicken GnRH II 
(cGnRH II , Miyamoto et al., 1984), lamprey GnRH I (Sherwood et al., 1986), catfish 
GnRH (Ngamvongchon et al., 1992), dogfish GnRH (Lovejoy et al., 1992), lamprey GnRH 
III (Sower et al., 1993), seabream GnRH (Powell et al., 1994), tunicate GnRH I (Powell et 
al., 1996), and tunicate GnRH II (Powell et al. , 1996) (Fig. 1.1 ). 
1 2 3 4 5 6 7 8 9 10 
Fig. 1.1 Comparison 
of the primary 
manunal pGlu His Trp Ser Tyr Gly Leu Arg Pro GlyNH2 structures between 
chicken I pGlu His Trp Ser Tyr Gly Leu Gin Pro GlyNH2 eleven types of 
seabream pGlu His Trp Ser Tyr Gly Leu Ser Pro GlyNH2 GnRHs. The amino 
Salmon pGlu His Trp Ser Tyr Gly Trp Leu Pro GlyNH2 acids differing from 
catfish pGlu His Trp Ser His Gly Leu Asn Pro GlyNH2 those of manunalian 
dogfish pGlu His Trp Ser His Gly Trp Leu Pro GlyNH2 GnRH are indicated 
chicken IT pGlu His Trp Ser His Gly Trp Tyr Pro GlyNH2 in red letters. 
lamprey ill pGlu His Trp Ser His Asp Trp Lys Pro GlyNH2 
lamprey I pGlu His Tyr Ser Leu Glu Trp Lys Pro GlyNH2 
tunicate I pGlu His Trp Ser Asp Tyr Phe Lys Pro GlyNH2 
tunicate n pGlu His Trp Ser Leu Cys His Ala Pro GlyNH2 
The GnRH isoforms are all decapeptides, which have been highly conserved through 
several hundred million years of evolution. Residues 1, 2, 4, 9, and 10 of the peptides are 
100 % conserved. Trp at position 3 is conserved in all forms, except for lamprey I. The 
amino acid at position 8 is not conserved. The NH2 - and COOH-terminal sequences of the 
peptides are highly conserved, and it has been proposed that both termini are important for 
receptor binding. The NH2 terminus is also responsible for receptor activation in mammals 
and chicken (Millar et al. , 1989; Davidson et al. , 1990; Sealfon et al., 1997). In most 
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species, at least two different GnRH isoforms are found: chicken IT, and a second / third 
form which varies in the different species (King and Millar, 1997). Two isoforms of 
GnRH, cGnRH I and cGnRH II, have been isolated from the hypothalamus and brain of 
chickens. Their structures differ from that of the mammalian counterpart, in that positions 




, respectively (Fig. 
1.1). 
Distribution : The embryonic development of the GnRH neuronal system has 
been studied extensively in many species by using immunocytochemical methods. In the 
chicken, the neurones expressing cGnRH I originate within nasal structures and migrate 
into the brain (Norgren and Lehman, 1991). In days 4 and 5 of the chicken embryo, a 
small cluster of cells of immunoreactive (ir)-GnRH neurones are found in the epithelium 
of the ventral olfactory pit. In E7, most of the ir-GnRH neurones are found in the medial 
half of the olfactory nerve and along the medial half of the telencephalon. The final 
destinations of ir-cGnRH I neurones are distributed in the medial preoptic area, the 
medial septum, the nucleus dorsomedialis anterior thalamus, the nucleus supraopticus, 
and the nucleus accumbens (Fig. 1.2). In addition, the ir-cGnRH I fibres occur throughout 
the preoptic area and in ventral portions of the septal region, and terminate in the 
palisade layer of the median eminence (Millam, et al., 1993). A similar origin and 
migration have also been observed in mammals (Schwanzel-Fukuda and Pfaff, 1989; 
1990; Ronnekleiv and Resko, 1990; Quanbeck et al., 1997) and in amphibians (Setal6, 
1996). 
The neurones expressing cGnRH II do not appear to differentiate from the 
olfactory placode, because the neurones are still found in the fetal brains of chickens after 
bilateral olfactory placode ablation during an early stage of embryogenesis (Akutsu et al., 
1992; Norgren and Gao, 1994). The ir-cGnRH II neurones are located along a 
dorsoventral line extending from the ventral border of the substantia grisea centralis to the 
dorsal border of the nucleus ruber, and also observed slightly medial to the nucleus of the 
basal optic root (Fig. 1.2). The fibres of cGnRH II are prominent in the nucleus 
preopticus medialis, and no fibres are detected in the median eminence (Mikami et al., 
1988; Sharp et al., 1990; Millam, et al., 1993). 
7 
Fig. 1.2 Diagram of the distribution of ir-cGnRH I and ir-cGnRH II 
neurones in turkey hen brain (Millam et al., 1993). Three major 
groups of ir-cGnRH I neurons are indicated and they are lateral 
ventricular group (triangles), basotelencephalic group (closed circles), 
midline group (diamonds). Two groups of ir-cGnRH II neurons are 
magno-cellular group (large open circles) and parvicellular group 
(small open circles). 
Cb: cerebellum; NC: neostriatum caudale; Get: substantia grisea centralis; CP: comm.issura 
posterior; HL: nucleus habenularis lateralis; EW: nucleus of Edinger-Westphal; DMP: nucleus 
dorsomedialis posterior thalami; nIV: nervus trochlearis; FLM: fasciculus longitudinalis 
medialis; OMd: nucleus nervi oculomotorii, pars dorsalis; Ru: nucleus ruber; NIII: Nervus 
oculomotorius; CA: comm.issura anterior; VL: ventriculus lateralis; TSM: Tractus opticus; 
POM: nucleus preopticus medialis; CO: chiasma opticum; ME: median eminence. 
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Physiological roles : As to the biological functions of cGnRH I and II in chicken, 
it has been suggested that according to the regional brain distribution of both hormones, 
cGnRH I, but not cGnRH II, plays an important role in regulating the pituitary-gonadal 
axis. 
It has been shown that both cGnRH I and II stimulate LH and FSH release in vitro 
in chickens (Millar et al., 1986; Hattori et al., 1986). cGnRH II is approximately 6-fold and 
13-fold more potent than cGnRH I in releasing LH and FSH, respectively ( Millar et al., 
1986). On the other hand, some studies have shown that cGnRH I and II are equipotent in 
releasing LH from anterior pituitary glands ( Hattori et al., 1986; Chou et al., 1985). The 
conflicting effects of cGnRH I and II might be due to sex differences in the LH responses. 
cGnRH I and II show more rapid and greater effects in cockerels than in hens (Sharp et al., 
1987). 
Although cGnRH II stimulates LH and FSH release in chickens, it does not have a 
physiological role on regulating the pituitary-gonadal axis. As mentioned earlier, cGnRH II 
is undetectable in the medium eminence. Several other points of evidence support this 
conclusion. The amounts of hypothalamic cGnRH I show changes that correlate with the 
different reproductive states of chickens (Sharp et al., 1990). In this study, the amount of 
cGnRH I in the median eminence is higher in laying than in out-of-lay hens. Passive 
immunisation with anti-cGnRH I, but not anti-cGnRH II, disrupts egg production. 
Moreover, the content of cGnRH I in the hypothalamus is increased in somatically 
immature birds after castration and in cockerels at the onset of puberty. There are no 
correlated changes in the amounts of hypothalamic cGnRH II in the same experimental 
samples. The expression of the cGnRH I gene is closely associated with the changes of 
plasma LH and ovary weight in laying and incubating hens (Dunn et al., 1996). In 
European starlings, the changes of cGnRH I neurones in number and size are associated 
with the photoperiodically-induced reproductive cycle (Parry et al., 1997). 
The physiological importance of cGnRH II remains elusive. The peptide might play 
a role as a neurotransmitter or neuromodulator in extra-hypothalamic areas of the brain. It 
has been suggested that cGnRH II might play a specific role in the medulla, an area whfch 
contains the highest concentration of cGnRH-11 in non-mammalian vertebrates (King and 
Millar, 1997). In ring doves, cGnRH II impacts on the reproductive behaviour after being 
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injected into the third ventricle (Besmer et al., unpublished). In amphibians, brain 
concentrations of cGnRH II exhibit significant reproductive status-related fluctuations in 
Rana esculenta (Rastogi et al., 1997). In the sympathetic ganglia of bullfrogs, cGnRH Il 
is the most potent peptide in inhibiting M current among GnRH analogues (Jones, 1987). 
Recently, cGnRH II was identified in sympathetic ganglia by a cGnRH II antiserum and 
co-eluted with synthetic cGnRH II on a HPLC gradient (Troskie et al., 1997). 
Additionally, its specific receptor has been detected by radio-ligand binding assay 
(Troskie et al., 1997). cGnRH II may have other functions. Moreover, cGnRH Il has been 
found in the goldfish pituitary, and it plays a role in stimulating GH secretion (Chang et 
al., 1990; Cook eta/., 1991). 
1.2 The TRH and GnRH receptors 
TRH and GnRH exert their hypophysiotropic effects through binding to their 
specific receptors on the surfaces of cells in_ the pituitary gland. These interactions result 
in conformational changes in the receptors and allow them to interact with the 
heterotrimeric G-proteins in the cell membranes which in turn promote second messenger 
signalling cascades to trigger biological actions of the hormones (see review, Sealfon et 
al., 1997; Gershengom et al., 1996). The structures of the cloned TRH and GnRH 
receptors reveal that both receptors are members of the G protein-coupled receptor 
(GPCR) family. 
1.2.1 Features of G protein-coupled receptors 
Members of the GPCRs family (approaching 1000 members) are characterised by 
seven hydrophobic stretches of 20-30 amino acids, which are predicted to form 
transmembrane (TM) a helices. These helices are connected by alternating hydrophilic 
extracellular loop (EL) and intracellular loop (IL), and an extracellular N-terminal, and an 
intracellular C-terminal domain (Strader et al., 1994). The TM domains are the most 
conserved , whereas the N- and C-terminal domains and IL 3 can be quite divergent 
(Dohlman et al., 1987). 
GPCRs have a wide variety of agonists ( e.g. cations, small biogenic amines, 
peptides, proteolytic enzymes, glycoprotein hormones) that stimulate the diverse second-
messenger pathways. However, these receptors share considerable structural homology. 
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The primary sequence identity in the TMs of these receptors ranges from 85-95 % for 
species homologues of a given receptor, to 60-80 % for related subtypes of the same 
receptor, and 35-45 % for other members of the same family, down to 20-25 % for 
unrelated GPCRs (Strader et al., 1994). 
All of the GPCRs have at least one consensus sequence for N-linked glycosylation 
(Asn-X-Ser/fhr) in ELs. It has been shown that glycosylation plays a role in receptor 
expression or stability in the fn-adrenergic receptor (~2AR), rhodopsin, and mammalian 
GnRH receptors (Rands, et al., 1990; Liu et al., 1993; Davidson et al., 1995). 
GPCRs contain a number of conserved cystein residues. There are two highly 
conserved Cys residues in EL 1 and 2, which have been shown to form a disulphide bond 
to maintain the active conformation of the receptor in ~2AR, rhodopsin (Dixon et al., 
1987a; Dohlman et al., 1990), mouse TRH receptor (Perlman et al., 1995), and 
mammalian GnRH receptors (Davidson et al., 1997; Cook and Eidne, 1997). 
Additionally, many GPCRs possess a Cys residue in the C-terminal tail. This residue has 
been shown to be palmitoylated in a-, ~-ARs (O'Dowd et al., 1989; Kennedy and 
Limbird, 1993), and rhodopsin (Ovchinnikov et al., 1988; Papac et al., 1992). It has been 
speculated that the palmityl group may anchor part of the cytoplasmic tail of the receptor 
to the plasma membrane, which is important for interactions with G protein. Intriguingly, 
the homologous Cys residues in the mouse TRH receptor are not necessary for G protein 
coupling, but may play a role in restraining the receptor in an inactive conformation that 
is optimal for rapid internalisation of the receptor (Nussenzveig et al., 1993a). 
The Asp-Arg-Tyr motif (DRY) adjacent to TM 3 is a highly conserved intra-
cellular sequence in GPCRs. The DRY motif has been implicated in signal transduction 
(see review, Probst et al., 1992). The highly conserved residue Asp in TM 2 plays a role 
in ligand binding and G protein activation in many GPCRs (Strader et al., 1987; 
Horstman et al., 1990; Wang et al., 1993). In addition, the membrane proximal regions of 
the third intracellular loop (IL) are necessary for G protein coupling in a number of 
GPCRs (Cotecchia et al., 1990; Baldwin, 1994). There are a series of conserved helix-
breaking Pro residues in each ofTMs 4, 5, 6, and 7, whose role is proposed to transfer the 
energy of agonist binding to conformational changes in ILs that allow association with G 
proteins (Millar and King, 1994). 
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1.2.2 The putative binding domains of GPCRs 
Structural interactions between ligands and receptors have been extensively studied 
for many members of GPCRs by a variety of approaches ( e.g. mutagenesis, computer 
modelling, biophysical analysis). Experimental data has revealed that different subfamilies 
of GPCRs (biogenic amine receptors, peptide receptors, and glycoprotein hormone 
receptors) possess different key elements in receptor binding. In general, the ligand binding 
sites of biogenic amine receptors reside within the TM domains, whereas the binding sites 
of peptide and glycoprotein hormone receptors are present in TMs, ELs, and the N-
terminus. 
The binding domain of biogenic amine receptors: 
The biogenic amine receptors [e.g. ex-, .B-adrenergic receptor (ex-, · .B-AR), 
muscarinic receptor, dopamine receptor (DAR), and serotonin receptor (5HT-R)] contain 
an acidic group in the binding pocket to provide a counterion for the protonated amine of 
the ligand. Asp113 in the TM 3 domain has been identified in .B-AR by mutagenesis as the 
counterion for the amine groups of the ligands (Strader et al., 1987). This Asp also has 
been found at homologous position in ex-AR (Wang et al., 1991) and muscarinic receptors 
(Fraser et al., 1989). Asp79 in TM 2 also plays a role in receptor binding and transduction 
in biogenic amine receptors (Strader et al., 1987; Horstman et al., 1990; Wang et al., 
1993). Additionally, Ser204 and Ser2°
7 in TM 5 (Strader et al. , 1989) and Phe290 in TM 6 
(Dixon et al., 1988) of the .B-AR form hydrogen bonds with the aromatic catechol moiety 
of .B-adrenergic agonists. It has been demonstrated that the hydrophilic loop regions of the 
receptors are not important for receptor binding (Dixon et al., 1987b ). 
The binding domain of peptide receptors: 
The peptide receptors of GPCRs include TRH, GnRH, neurokinin (NK), substance 
P, angiotension (AT), neuropeptide and glucagon receptors, whose natural ligands range 
from 3-40 amino acids in size. It has been proposed that the peptide-binding sites of 
GPCRs contain a larger surface area than that of biogenic amine receptors. Mutagenesis 
studies have suggested that the extracellular domains of receptors may provide additional 
contact sites for peptide ligands. For example, in the NK 1 receptor, Asn
23
, Gln24, and 
Phe25 in the N-terminus and Asn% and His
108 in EL 1 are required for the high-affinity 
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binding of NK. (Fong et al., 1992). In the AT receptor, the N-terminus (His
24, Y26, and 
!27), EL 1 (Y92 and K 102), EL 2 (V179), and part of EL 3 are important for ligand binding 
(Hjorth, et al., 1994). In addition to residues in the extracellular domain, the TM regions 
are also critical for peptide binding for many GPCRs. For example, the residues Asn
85
, 
Asn89, Tyr92, Asn96 (in TM 2), and Tyr2
87 (in TM 7) of the NK. 1 receptor (Huang et al., 
1994) or the residues Lys113
 and Tyr129 (in TM 2) of the endothelin receptor (Zhu et al., 
1992) take part in receptor binding. 
The binding domain of glycoprotein hormone receptors: 
The extracellular domains, especially the N-terminal region, are also involved in 
ligand binding for the glycoprotein hormone receptors. The glycoprotein hormone 
receptors contain a vecy large N-terminus ranged at 300-400 amino acids. The N-terminal 
region of the lutropin receptor alone displays high affinity and specificity for LH (Tsai-
Morris et al., 1990). The N-terminus of the TSH receptor plays a pivotal role in the high- . 
affmity binding of its ligand (Nagayama et al., 1991). 
1.2.3 TRH receptor {TRH-R) 
General structural features : The TRH-R DNAs have been cloned from 3 
mammalian species: two isoforms from mouse (Straub et al., 1990; Duthie et al., 1993a), 
two isoforms from rat (De La Pefta et al., 1992; Sellar et al., 1993; Zhao et al., 1992), and 
human (Duthie et al., 1993b; Matre et al., 1993; Yamada et al., 1993), but not from any 
other vertebrate classes. The two variant forms of the TRH-R, from mouse or from rat, 
are characterised by different amino acid sequences in their respective C-terminal tails. 
The amino acid sequences of the TRH-R share over 90 % identity amongst the 5 cloned 
receptors. 
The structure of the TRH-R reveals that the receptor contains several residues 
which are highly conserved in GPCRs. Three potential sites for N-linked glycosylation 
are present in the N-terminal region (Asn
3 and Asn10 ) and in EL 2 (Asn
167
). Two Cys 
residues (Cys98
 and Cys179 ) in EL 1 and 2 of the receptor appear to form a disulphide 
bridge (Perl.man et al., 1995). Two additional Cys residues, Cys
335 and Cys337 , have been 
found in the C-terminal tail, but the palmitoylation in both loci is yet to be determined. 
Moreover, there are Ser and Thr residues in IL3 and in the C-terminal tail, which could 
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serve as sites for regulatory phosphorylation (Lefkowitz, 1993). In the TRH-R, several 
additional residues in the proximal and distal juxtamembrane regions of IL 3 are 
important for coupling to Gq111 , whereas a large part of the middle portion of the loop can 
be deleted without any effect on the coupling (Nussenzveig et al., 1993b). 
Ligand bindinr sites 
Th~ putative binding sites of the mammalian TRH-R have been identified by 





ryr2~7, and Arg306• The findings reveal that the interaction between TRH and its receptor 
is non-ionic, unlike the binding ofbiogenic amine receptors. 
Tyr10f: The Tyr residue in TM 3 of the muscarinic receptor is involved in 
ligand binding by fonning an hydrogen-bonding connection with ligand. Amongst 
mutations of several residues that could form an hydrogen bond with TRH, Tyr
106 of the 
TRH-R has been verified as the candidate residue in the mouse. Mutation of Tyr
106 to 
Phe, which abolishs the hydroxyl group of tyrosine, causes an unmeasurable level of 
affinity for TRH (Perlman et al., 1994a). Further study has revealed that the hydroxyl 
group ofTyr106 binds the carbonyl group of the pGlu
1 moiety ofTRH. 
Asn110 : According to the interactions between the pGlu moiety ofTRH and 
TM 3 of the TRH-R by computer modelling, it shows that the ring N-H of Glu interacts 
with the side chain C=O of Asn
110
• Mutagenesis of Asn
110 has confirmed the importance 
of Asn110 in ligand binding (Perlman et al., 1994b). 
Tyl82 and Arg106 : A three-dimensional model of the TRH-R reveals 
that Tyr282 in TM 6 forms an hydrophobic interaction with the imidazole of the His 
residue of TRJI ~d Arg
306 forms hydrogen bonds with C=O of pGlu and C=O of ProNH2 
ofTRH (see review, Gershengorn et al., 1996). 
Ligand-selectivity of TRH receptor : 
Structure-function activity studies of many TRH analogues have established that 
the side chains of all three amino acid residues of TRH are involved in binding to the 
TRH-R. Most TRH analogues bind the receptor with low affmity. Only one TRH 
analogue, Nr -[ methyl]His-TRH, shows about an 8- and 2-fold increase in stimulating 
TSH release in vivo and in vitro, respectively (Vale et al., 1971). This can be attributed to 
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a greater binding affinity for the receptor (Perlman et al., 1994b) and/or an increased 
efficacy to trigger the secondary messenger. 
G protein coupling: The TRH-R has been shown to couple to Gq and G11, which 
activate phophoinositide-specific phospholipase C (PPI-PLC) in GH3 cells and in HEK-293 
cells expressing mammalian TRH receptors (Aragay et al., 1992; Hsieh and Martin, 1992; 
Hepler and Gilman, 1992; Kim et al., 1994). Some findings suggest that the TRH-R 
couples to other G proteins. Gollasch et al. (1993) have provided evidence that Gi-2 and Gi-3 
are involved in the TRH stimulation of voltage-sensitive calcium channels in GH3 cells. 
There are controversial findings in the TRH-R coupling to Gs that is known to activate 
adenylyl cyclase and calcium channels and to inhibit sodium channels (Hepler and Gilman, 
1992). One investigator group has suggested that the TRH-R couples to Gs and stimulates 
adenylyl cyclase in GH3 cells (Paulssen et al., 1991; 1992). However, most findings do not 
support the evidence for TRH stimulation of adenylyl cyclase in GH3 cells or in other cell 
types expressing mammalian TRH receptors (Heinflink et al., 1994; Kim et al., 1994; 
Quick et al., 1994). In chickens, cAMP may participate in the effect of TRH-induced GH 
release (Perez et al., 1989). Some findings indicate that a Gs-like protein is involved in 
TRH stimulation of a rise in intracellular free calcium in GH3B6 cells (Bauer et al., 1994) 
and in TRH stimulation of PPI-PLC in Xenopus oocytes expressing the mammalian TRH-
Rs (De la Pefia et al., 1995). However, a finding suggests that coexpression of the TRH-R 
and Gs does not affect signalling through PPI-PLC inXenopus oocytes (Quick et al., 1994). 
1.2.4 GnRH receptor (GnRH-R} 
General structural features: The GnRH-R has been cloned from several 
mammalian and a non-mammalian species: mouse ( Tsutsumi et al., 1992), rat (Eidne et 
al., 1992; Kaiser et al., 1992; Perrin et al., 1993), human (Kakar et al., 1992; Chi et al., 
1993), sheep (Brooks et al., 1993; Illing et al., 1993), cow (Kakar et al., 1993), pig ( 
Weesner et al., 1994), and catfish (Tensen et al., 1997). In the comparison of amino acid 
sequences, the mammalian GnRH-Rs share over 85 % amino acid identity. However, the 
catfish GnRH-R, the only non-mammalian receptor that has been cloned, shares only 40 % 
identity with the human GnRH-R. As compared to other GPCRs, the mammalian GnRH-Rs 
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possess several unusual or unique features. These include a complete absence of the 
intracellular C-terminal tail, the change of the highly conserved Asp-Arg-Tyr (DRY) 
sequence to Asp-Arg-Ser (DRS) at the end of TM 3, and the reciprocal exchange of the 
conserved TM 2 Asp and TM 7 Asn. However, the catfish GnRH-R has a C-terminal tail. 
The C-terminal tail has been demonstrated to play a role in receptor palmitoylation 
(Ovchinnikov et al., 1988), homologous desensitisation in GPCR receptors (Bouvier et al., 
1988; Widmann et al., 1997)), and internalisation (Widmann et al., 1997). Mutagenesis 
studies of the mammalian GnRH-Rs have identified glycosylation sites in the N-terminal 
domain (Asn4 and Asn8) in the mouse GnRH-R (Davidson et al., 1995). Mutation of the 
Asn4 or Asn8 to Gin results in lower expression of the receptor than that of the wild type 
receptor. However, the ligand-binding affmities of the mutated receptors are unchanged. 
Additionally, disulphide bonds in the mammalain GnRH receptors have been verified by 
photo-affinity cross-link and mutagenesis studies (Davidson et al., 1997; Cook and Eidne, 
1997 ). The bonds are located at two different places: between Cys
14 (in N-terminus) and 
Cys200 (in EL 2) and between Cys
114 (EL 1) and Cys196 (EL 2) in the human GnRH 
receptor, whereas only residues Cys
114 and Cys195 form a disulphide bridge in the rat 
receptor. The disulphide bridges are essential for receptor binding and activation. 
Furthermore, the residues Asn
87 (TM 2) and Asp318 (TM 7) of the mammalian GnRH-Rs, 
in which the analogous positions are TM 2 Asp and TM 7 Asn in most GPCRs, have been 
shown to interact with each other (Zhou et al., 1994). Substitution of Asn
87 to Asp 
abolishes receptor function (binding and IP formation). Interestingly, the reciprocal 
mutation (Asp87 and Asn
318
) restores the receptor binding; however, the mutant receptor 
exhibits very poor IP formation. The fmding indicates that the two residues might be 
involved in the active conformation of receptor. 
Ligand binding sites 
Several putative ligand interacting sites have been identified in the GnRH receptor 
by site-directed mutagenesis studies. The putative binding sites contain Glu
301 
( or Asp302 in 
human GnRH-R), Lys
121
, and Asn102 in mouse GnRH-R. 
Gt,/01 (or Asp362 ): The fmdings of the GnRH-R binding studies reveal 
that the Arg8
 residue of mGnRH is critical for high affmity binding of the mammalian 
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GnRH-R. Therefore, it has been postulated that the positively-charged Arg
8 of mGnRH 
might interact with a negatively-charged acidic amino acid residue or sialic acid residue in 
the receptor. However, the polysaccharide sialic acid residues do not affect ligand 
binding (Davidson et al., 1995). Amongst mutations of all acidic amino acids in ELs, 
Glu301 of the mouse GnRH-R (or Asp
302 of the human receptor) in EL 3 has been 
identified as the candidate for interacting with the Arg
8 residue of mGnRH (Flanagan et 
al., 1994). In this study, the substitution of Glu
301 with Gin301 results in a 100-fold 
reduction in affinity for [Arg8]-GnRH; however, the mutant receptor exhibits unchanged 
affinity for [Gln8]-GnRH and increased affinity for [Glu
8]-GnRH. The finding indicates 
that the Glu301 plays a critical role in identifying the positive charge of [Arg
8]-mGnRH. 
Ly/21 : It has been demonstrated that the highly conserved Asp 
residue in TM 3 of biogenic amine receptors acts as the counterion for amine ligands 
(Strader et al., 1987). Therefore, the homologous residue of the GnRH-R, Lys
121, might 
take part in the receptor binding. The Lys
121 residue was mutated to Asp, Ala, Leu, or Gin 
and the mutations cause more than 1000-fold reduction in affinity of agonist binding, 
whereas the mutant receptor (Lys121Gln) exhibits normal antagonist binding (Zhou et al., 
1995). Moreover, the Lys121 might interact with His2 or pGlu
1 of GnRH (Zhou et al., 
1995). 
An/02: Another putative binding site of the GnRH-R has been 
located in the junction between TM 2 and EL 1. Mutation of Asn 
121 to Ala leads to a 100 
- 1000-fold reduction in affinity for GnRH analogues which contain the GlyNH2 
carboxy-terminal residue, but shows only a slight effect on that of ligands containing N-
ethylamide at the carboxyl-terminus (Davidson et al., 1996). The result suggests that the 
Asn121 residue of the GnRH-R might directly interact with Gly
10 NH2 of GnRH 
analogues. 
Ligand-selectivity of GnRH receptor : Through 500 million years of 
evolution, all the vertebrate GnRHs are active in all vertebrates, but differences in ligand-
selectivity exist amongst vertebrate GnRH-Rs. Non-mammalian vertebrate GnRHs have 
been shown to have relatively poor activities of receptor binding and gonadotrophin 
release in mammalian systems, whereas all of these GnRHs (with the exception of 
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lamprey GnRH II) have relatively high activity in birds, reptiles, amphibians, bony fish, 
and cartilaginous fish (see review, King and Millar, 1997). 
Previous studies have shown that the chicken receptor has dramatic differences in 
ligand-selectivity as compared with that of the mammalian receptor. The chicken receptor 
can not discriminate basic or neutral amino acids in the position 8 residue of GnRHs, 
while the mammalian receptor has a specific preference for Arg in this position (Millar et 
al., 1989). In addition, His
5 accompanying Arg
8 in analogues markedly diminishes 
activity in the chicken, whereas gonadotrophin-releasing activity is retained in the sheep 
pituitary. Interestingly, 2 out of 10 selected mammalian GnRH antagonists exhibit agonist 
effects in the chicken (Jacobs et al., 1995). There are differences in ligand-selectivity 
amongst other non-mammalian GnRH receptors. Signalling studies (measuring inositol 
phosphate production) reveal that all of the cloned· non-mammalian GnRH-Rs (the 
chicken, frog, goldfish, and catfish receptors) show a striking preference for cGnRH II 
(20-1000 times more active than any other ligand), whereas cGnRH II has relatively low 
activity in mammalian receptors (Millar et al., 1997; Tensen et al., 1997). The chicken 
receptor does not distinguish between mGnRH and cGnRH I, whereas mGnRH exhibits 
200-fold more activity than cGnRH I for the frog receptor and 1000-fold more activity 
than seabream GnRH for the goldfish receptor (Millar et al., 1997). 
G protein coupling : The mechanism of GnRH stimulation of gonadotrophin 
secretion from anterior pituitary gonadotrope cell may be divided into three steps: i) 
GnRH binding and activation of the receptor; ii) intracellular signal transduction; iii) 
exocytosis of gonadotrophin-containing secretory granules. GnRH exerts its physiological 
role, firstly, via binding to its specific receptor (GnRH-R) in the membrane of 
gonadotrophs; then, coupling to G-proteins (Gq and/or G 11) which in turn promotes 
secondary messengers [1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3)]. 
IP3 activates a calcium release channel in the endoplasmic reticulum membrane, there by 
allowed calcium to flood the cytosol, while DAG activates protein kinase C. This 
signalling cascade triggers gonadotrophins (LH and FSH) release (Hsieh and Martin, 
1992). In chicken pituitary cells, GnRH causes a rapid initial spike ofLH release from 0-5 
min, followed by a prolonged plateau phase of release. The spike phase of GnRH-induced 
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LH release was partially dependent on extracellular calcium. In contrast, the plateau phase 
ofLH release was completely dependent on extracellular calcium. 
1.3 Aims of this study 
GnRH analogues are extensively used as therapeutic agents in several disorders, 
such as precocious puberty (Comite et al., 1981), endometriosis (Meldrum et al., 1982), 
prostate and breast cancers (Borgmann et al., 1982) and infertility (Conn et al., 1984). 
Therefore, the molecular based knowledge of GnRH action, including interacting with its 
receptor (the binding domain) and signal coupling, are important in the development of 
novel analogues; especially non-peptide orally-active analogues. The chicken GnRH-R 
appears to have marked differences from the mammalian GnRH-Rs in ligand-selectivity 
and some mammalian GnRH antagonists appear to act as agonists. The molecular cloning 
and characterisation of the chicken GnRH-R would therefore provide the means for 
potentially identifying domains and residues involved in ligand-selectivity. The 
comparative sequences of the receptor may also assist in understanding molecular 
features associated with the configuration of the receptors, agonist-mediated activation, 
coupling, and desensitisation. Additionally, the chicken GnRH receptor will provide 
further insight into the development and reproductive physiology of chickens. 
The TRH-R will provide a useful tool for further studies on the roles of TRH in 
avian growth and thyrotrophin regulation. Moreover, the information of comparative 
amino acid sequences might give an insight into the knowledge of the structural 
conformation and regulation of the TRH-R receptor. 
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Cb11p1,r ~ 
Cloning and Characterisation of - chicken TRH Receptor (TRH-R) 
2.1 Abstract 
2.2 Introduction 





The chicken TRH-R cDNA has been cloned in this study, and shares about 80% 
amino acid homology with the mouse TRH-R. The ligand binding pocket, which is situated 
in the transmembrane domains of the mouse TRH-R, is completely conserved in the 
chicken TRH-R. Pharmacological studies (receptor binding and inositol phosphate 
production) employing several TRH analogues, reveal that there are no significant 
differences between the chicken and mouse TRH-R. These findings show that there have 
been considerable evolutionary constraints on the TRH-R structure and function. 
In addition to the full-length TRH-R cDNA, two isoforms of the TRH-R were 
identified while screening a cDNA library. Both isoforms had a stop codon at nucleotides 
+ 1006 (downstream), resulting in a receptor that prematurely terminated in the putative 
intracellular loop Ill. The 20 amino acids that precede the stop codon in these clones have 
no homology with mammalian TRH-Rs. The consensus 5'-end sequence of the exon-intron 
junction, AGgtag, is found at the point of homology divergence. The divergent region has 
been verified as an intron. 
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2.2 INTRODUCTION 
As covered in the general introduction ( chapter 1 ), thyrotrophin-releasing hormone 
(TRH: pGlu-His-ProNH2) is synthesised in the hypothalamus, and is transported via the 
hypophysial portal circulation into the pituitary gland to regulate the biosynthesis and 
release of thyrotrophin (TSH). It also functions as a paracrine regulatory factor and a 
neurotransmitter/ neuromodulator in central and peripheral nervous systems (Metcalf and 
Jackson et al., 1989). In addition to these physiological roles, TRH is·well documented as a 
potent growth hormone-releasing factor (GRF) in birds (Harvey, 1990a). In the chicken, 
TRH stimulates growth hormone (GH) release in vivo and in vitro, and the effect is even 
more potent than that of mammalian GRF (Harvey et al., 1984; Harvey et al., 1985). TRH 
exerts these physiological roles by binding to its specific receptor (TRH-R) on the 
membranes of somatotrophs and thyrotrophs (Dannies et al., 1976; Harvey and Baidwan, 
1989; Sharif, 1989). 
To date, five types of TRH-R cDNAs have been cloned from 3 species of the 
mammal (as indicated in "introduction"). The structure of the TRH-Rs reveals that the 
receptor is a member of G-protein coupled receptor family, consisting of seven 
transmembrane (TM) helixes. The receptor has been shown to couple to several G-proteins 
(e.g. Gq,Gll,Gi-2, Gi-3, and a Gs-like protein that does not activate adenylyl cyclase) which 
in turn promotes secondary messengers (DAG, IP3, and Ca J signalling cascade after 
being bound by its ligand (see review Gershengom and Osman et al., 1996). On the 
contrary, some findings suggest that TRH-R couples to Gs and stimulates adenylyl cycla.se 
in GH3 cells (Paulssen et al., 1991; Paulssen et al., 1992). In chickens, cAMP may 
participate in the effect ofTRH-induced GH release (Perez et al., 1989). 
This study has been undertaken to clone the TRH-R gene from chickens and 
pharmacologically characterise the receptor by measuring inositol phosphate and cAMP 
formation. This study provides a useful tool for further studies on the roles ofTRH in avian 
growth and thyrotrophin regulation. Furthermore, the cloning of the TRH-R cDNA shows 
that this receptor has been highly conserved through millions of years of evolution, as it 
retains a large degree of homology with mammalian receptors. 
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2.3 MATERIALS AND METHODS 
Materials 
The oligo-nucleotides (primers) used in the cloning of the TRH-R cDNA are 
summarised in Table 2.1, and their positions on the chicken TRH-R cDNA are illustrated 
in Fig. 2.1. 






















Fig. 2.1 The locations of the primers used in this study. 
The nucleotide sequences of the primers were derived from the 
chicken TRH-R cDNA (top panel) and a truncated TRH-R cDNA 
(bottom panel). EBl: a primer of the mouse TRH-R; ORF: open 
reading frame; TM: transmembrane; "•": stop codon; "AGgtag": 
the consensus 5'-end sequence of the exon-intronjunction. 
+l 
ORF 




AGgtag atop codon 
The primary structure of TRH analogues that were used in this study and their source are 
presented in the following Table (2.2). 
Structure Source 
Analogues 1 2 3 
TRH pyroGlu His Pro-NH2 Sigma Chemical Co. 
DesavlTRH pyrolidone His Pro-NH2 
a gift from the late Dr. L.A. Cohen 
(Bethesda, MD, USA) 
vafTRH pyroGlu Val Pro-NH2 Peninsula Laboratories (Belmont CA, 
Phe1TRH pyroGlu Phe Pro-NH2 USA) 
MeTRH pyroGlu Nr·[methy/]His Pro-NH2 Sigma Chemical Co. 
PyrTRH pyroGlu His Pyrrolidine Dr. T.K. Sawyer (Parke-Davis 
Pharmaceutical Research) 
Methods 
2.3.1 Cloning chicken TRH-R gene 
Constructing the cDNA library from the chicken pituitary gland 
In order to clone the chicken TRH-R gene, the cDNA library of the chicken 
pituitary gland was constructed. The first step for constructing a cDNA library was to 
prepare pure poly(A/ RNA (about 5 µg) of the chicken pituitary gland, since 5 µg of 
poly(A/RNA is optimal for constructing a good library. 
Total RNA was isolated by the guanidinium thiocyanate-phenol-chloroform 
extraction method (Chomczynski et al., 1987) from 70 chicken pituitary glands (Golden 
Grove Poultry Company, Cape Town, South Africa). 6.6 µg of poly(A/ RNA of the 
chicken pituitary was purified with affinity chromatography using an oligo ( dT)-cellulose 
column (made by myself). The column was made by means of a 1ml pipette tip, plugged 
with glass wool (about 0.5 mm) at the neck. 1ml slurry of oligo (dT)-cellulose (25mg) 
was poured into the column. The column was rinsed with 10 ml d.d.H20, and equilibrated 
with 30 ml of lx loading buffer [containing 0.5 M LiCl, 10 mM Tris-Cl (pH: 7.5), 1 mM 
EDTA, 0.1 % ofSDS, and 0.1 % diethylpyrocarbonate]. 
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1 µg of poly(A/RNA was analysed on an RNA gel to evaluate the quality, and 
compared with the total RNA ( Fig. 2.2). There was veiy little 28S and 18S of rRNAs existing 
in the sample of the first eluting fraction, suggesting that the first eluting sample contained veiy 
pure poly(At RNAs. There was no poly(At RNA eluted at the second and third fractions, 
indicating that the "home-made" oligo( dT) column worked veiy well. 
Fig. 2.2 Electrophoresis of the poly(A)+ RNA of the chicken pituitary 
gland, eluted consecutively from an oligo( dT ) column on an 
1% agarose formaldehyde denaturing gel. 18S and 28S of the 
rRNAs are indicated. 
Lane 1: Total RNA isolated from the chicken pituitary (before 
passing the column). 
Lane 2: the first eluting fraction. 
Lane 3: the second eluting fraction. 





1 2 3 4 
5 µg of the poly(At RNA of the chicken pituitary gland were used to construct a 
cDNA library in the Uni-ZAP XR vector digested with EcoR I / Xho I, according to the 
instruction of the ZAP-cDNA synthesis kit (Stratagene, 1994). The procedure is 
summarised in Fig. 2.3. 
Fig. 2.3 The procedures for constructing the cDNA 
library from the chicken pituitary gland. 
A. Synthesis offirst-strand cDNAs 
5 µg poly(At RNA extracted from chicken 
pituitary glands was used to synthesise first-
strand cDNA, initiated by a 50-base oligo 
which contained an oligo (dT) 18 and a Xho 
I recognition site. 
B. Synthesis of second-strand cDNAs 
mRN 
A y y 
3, ------AAA .. AAA ______ TIT .. ""'I .... 11rrc::;::i--,
5
, 
Flnt 1tnad OUgo(dT) prl-'f' 
cDNA Xho I site 
S' 
Second stnnd cDNA AAA .. AAAr-, 
3' 
The second-strand cDNAs were synthesised 
at l 6 °C for 2.5 h, using the first-strand 
cDNAs as templates and primed by a 
multitude of RNA fragments which was 
nicked by RNase H. 
Finl strand cDNA 
-----TIT .. TIT L_J S' 
C. Ligating EcoR I adapters onto the 
double-strand cDNAs 
The EcoR I adaptors were ligated at both 
ends of cDNAs. 
D. Ligating cDNAs into the Uni-ZAP XR 
vector arms 
The double-stranded cDNAs were size-
selected using Sephacryl S-400 Columns and 
subcloned into the Uni-ZAP XR ).. vector 
( digested with EcoR J/Xho I). 
E. Packaging 
The lambda library was packaged into ).. 
phage heads. 
F. Titration and ampli[u:ation ofthe cDNA 
library 




S' Adaptor Adaptor 3' 
3' 
AAA . .AAA[j ·' TIT .. TIT 




phage phage phage 
Phage 
plaques 
Firstly, first-strand cDNAs were synthesised by M-MuL V Reverse Transcriptase from 
5 µg poly(A/ RNAs with a linker-primer which contained an oligo(dT)18 and a Xho I 
recognition site. This step was carried out at 37 °C for 1 h. A control for first-strand cDNA 
synthesis was included by incorporating a 32P-labelled dCTP (800 Ci/mrnol, Amersham) into 
5 µl of the first-strand cDNA reaction mixture. After 1 h, the reaction was stopped by putting 
the tube containing the mixture on ice. Second-strand cDNAs were synthesised using the first-
strand cDNA as a template with DNA polymerase I and were initiated by a multitude of RNA 
fragments which were nicked by RNase H from the RNA-DNA chimerical strands. A trace 
amount of a 32P-labelled dCTP (800 Ci/mrnol, Amersham) was included in the second strand 
reaction to monitor the synthesis. The reaction of second-strand cDNA synthesis was 
incubated at 16 °C for 2.5 h. After synthesis for 2.5 hat 16 °C, the reaction was terminated by 
putting the reaction on ice. Double-stranded cDNAs were purified by phenol 
(pH:8.0):chloroform [1 :1 (v/v)] and precipitated by 1/10 Vol. of 3 M sodium acetate and 2.5 
Vol. of 100 % ethanol. The quality of the first-strand and second-strand cDNAs of the library 
was analysed on a gel (Fig.2.4). A lot of high molecular weight products (> 1 kb) were 




0.8 kb _. 
Fig. 2.4 Autoradiograph of the first-
strand and second-strand 
cDNAs synthesised during the 
construction of the chicken 
pituitary cDNA library. The 
samples, which were 
incorporated with a 32P-labelled 
dCTP, were analysed on 1 % 
alkaline agarose gel. 0.8 and 1 
kb sizes are indicated. 
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Lane 1: the first-strand cDNA. 
Lane 2: the second-strand cDNA. 
Then, the uneven termini of the double-stranded cDNAs were blunt-ended with Kienow at 37 
~C for 30 min and dephosphorylated EcoR I adaptors were ligated onto the ends of double-
stranded cDNAs by T 4 DNA ligase at 4 °C overnight. The EcoR I ends were treated with T 4 
kinase to enable their ligation into the dephosphorylated vector arms, and were digested with 
Xho I to release the EcoR I adaptor and residual linker-primer from 3' end of the cDNAs. 
Before ligating the double-stranded cDNAs onto the ZAP XR ,., vector arms, the 
digested cDNAs were purified and sized using a Sephacryl spin column. Six cDNA fractions, 
were collected and analysed on a sequencing gel to choose the fractions with large transcripts 
(Fig. 2.5). The first fraction from the spin column contained the largest cDNAs. 
Fig. 2.5 Size fractionation of the double-stranded cDNAs of the 
chicken pituitary gland. Six cDNA fractions were collected 
consecutively after passing through a Sephacryl spin column 
and analysed on a sequencing gel. 
Lane 
1 2 3 4 5 6 
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The concentration of the six fractions was quantified on an ethidium bromide plate, which 
contained known concentrations of DNA as standards (200 ng to 10 ng) ( Fig. 2.6). 
Fig. 2.6 Quantification of the six cDNA/ractions of the 
chicken pituitary gland, sized by passing through 
a Sephacryl spin column. Six cDNA samples were -----
applied to the central area. 
On the basis of these results (Fig. 2.5 and 2.6), the fraction 1 was chosen to be 
subcloned into the Uni-ZAP A vector, which was digested with EcoR I and Xho I. Finally, the 
vector was packed into 11. phage heads. The cDNA libraty was titred and amplified using E. coli 
(XL1-Blue) as the host. The phage lysate was collected from the lx 106 plaques, and was used 
to re-infect E.coli to amplify the cDNA library to a titre of 2.5x 109 plaques/ml. 
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Screening of the cDNA library ofthe chicken pituitary gland 
Approximately lxl06 recombinants were screened in 20 (150 mm) petri plates 
according to the protocol of Stratagene (1994). Duplicated nylon filters were lifted 
sequentially (1 min absorption for the first filter; 2min for the second), denatured in the 
solution containing 0.5 M NaOH and 1.5 M NaCl, neutralised in the solution [1.5 M NaCl, 
0.5 M Tris-HCl (pH: 7.2), and 0.001 M EDTA (pH: 8.0)] and baked at 80 °C for 20 min. A 
2.3 kb fragment of the mouse TRH-R cDNA (a gift from Prof. Gershengorn, Cornell 
University Medical College, New York, USA) was labelled with a 32P-dCTP (3000 
Ci/mmol, Amersham) by random hexamer priming using Megaprime labelling kit 
(Amersham). The filters were pre-hybridised at 42 °C in 50 % formamide solution 
(containing 0.8 M NaCl, 0.02 M PIPES, 50 % De-ionised formamide, and 0.5 % Sodium 
dodecyl sulphate). After 3 h pre-hybridisation, the labelled probe was added to the 
membranes and the hybridisation was carried out at 42 °C overnight. The filters were 
washed with lx SSC, 0.1 % SOS, at room temperature, for 15 min; 0.5x SSC, 0.1 % SOS, 
50 °C, for 30 min, and 0.2x SSC, 0.1 % SOS, 50 °C, for 20 min. Secondary and tertiary 
screenings for the positive clones were performed by the same procedures. 
Rescuing chicken TRH-R cDNA from the Uni-ZAP vector 
The positive clones, which were obtained from screening the cDNA library, were 
rescued from the arms of the Uni-ZAP vector by the ExAssist™/ SOLR™ system 
(Stratagene, 1994) for further characterisation. Positive clones from the tertiary screening 
were isolated from agar plates and were transferred to a sterile microfuge tube containing 
500 ml of SM buffer [0.1 M NaCl, 0.02 M MgS04, 50 ml of 1 M Tris-HCl (pH: 7.5), and 5 
ml 2% gelatine] and were incubated at 4 °C, overnight, to release the phage particles into 
the SM buffer. 200 µl of the SM buffer with 200 µl of XL1-Blue cells and I µl of ~ 08 
helper phage was cultured in 3 ml of 2x YT media (0.15 M of NaCl, 10 g of Yeast extract, 
and 16 g ofBacto-tryptone) for 2.5 hat 37 °C. The cells were shocked by heating to 70 °C 
for 20 min, then the cells were spun down at 4000 g for 5 min. The supernatant ( 
containing the pBluecript phagemid with the chicken TRH-R cDNA) was decanted into a 
sterile tube and stored at 4 °C. 
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3 'RACE (Rapid Amplification of the 3 'end) 
The first-strand cDNA of the chicken pituitary gland was synthesised by Reverse 
transcriptase (Strategene) with an oligo(dT)w adaptorB-adaptorA primer. Then, the 
second- strand cDNA was synthesised by the same procedure as described in "constructing 
cDNA library" section. PCR (polymerase chain reaction) was applied to amplify the 3' -end 
region of the chicken TRH-R gene by Taq polymerase (Amersham) with a pair of primers, 
adaptor B and CH2, which were shown in Table 2.1 and Fig. 2.1. The PCR samples were 
denatured at 93 °C for 4 min, and were subjected to 35 cycles (93 °C for 1 min, 60 °C for 2 
min, and 72 °C for 3 min). The samples were elongated at 72 °C for 6 min and were 
cooled down at 4 °C for 10 min. 
Amplification of the full-length chicken TRH-R cDNA 
The cDNA fragment of the chicken TRH-R, which encodes a region from EL 2 to 
TM 6, was amplified from the chicken pituitary cDNA by PCR with a pair of primers, i.e. 
a chicken specific primer CHI (sense) and a mutated mTRH-R primer EB 1 (antisense) (a 
gift from Prof. Gershengom) (shown in Table 2.1 and Fig. 2.1). Using this cloned fragment 
as a probe to screen the chicken cDNA library, 25 positive clones were isolated. Of the 25 
clones, 9 clones (Trun-4 to Trun-12) were identified by partial sequencing and by 
restriction enzyme mapping as incomplete receptor cDNAs, but contained an entire 3' -end 
region. Primer CH6 was designed, based on the sequences of the 3' end of TRH-R gene. 
The full-length cDNA of the chicken TRH-R was amplified by PCR with a pair of 
primers, CH5 and CH6, which flanked the entire open reading frame of the TRH-R (shown 
in Table 2.1 and Fig. 2.1 ). The cycles of PCR were described above. 
Sequencing 
Plasmid DNAs of 12 clones and full-length chicken TRH-R cDNA clones 
(amplified by PCR) and the constructed full-length clone (the chicken TRH-R cDNA) 
were purified by Wizard maxi preps column (Promega, USA) and sequenced manually, 
using a sequenase kit (U.S. Biochemical Corp.). To confirm the nucleotide sequences of 
the chicken TRH-R cDNA, the plasmid DNA was sequenced in both directions. 
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Identification ofthe divergent region ofthe truncated chicken TRH-R 
The truncated chicken TRH-R cDNA, Trun-1, -2, and -3 clones, were isolated from 
a cDNA library. They were identified by sequencing and all contained a premature stop 
codon (TAA) in the putative third IL 3. The 20 amino acids that precede the stop codon in 
these clones had no homology with the mammalian TRH-R. The region from the 20 amino 
acids onwards, was called a divergent region. To analyse the divergent region, firstly, the 
chicken TRH-R gene was isolated from a chicken genomic library constructed in 
bacteriophage 'A. Charon 4A (EcoR I digested) (Dodgson et al., 1979) by hybridising with 
a32P-labelled Trun-3 cDNA. Restriction enzyme digests of the chicken TRH-R genomic 
clone were subjected to Southern blot analysis by hybridising with probe A, which 
contained the coding region of TM 1 to most of IL 3; then stripped of the probe and re-
hybridised with probe B, containing an entire divergent region. PCR was applied to re-
confirm the location of the divergent region, by using two pairs of gene specific primers, 
CHI & CH4 and CH2 & CH3 (shown in Table 2.1 and Fig. 2.1). The cycles of PCR were 
described above. 
Northern blot analysis 
Total RNAs from the chicken and sheep pituitary glands, were isolated by the 
method as described (Chomczynski et al., 1987). The total RNAs (30 µg) from the two 
species, were analysed on a formaldehyde denaturing gel, and were transferred into the 
Hybond N membrane (Amersham). The samples were fixed in the membrane using a UV 
· crosslinker (Amersham). The membrane was hybridised with the full-length chicken TRH-
R cDNA, which was labelled with a 32P-dCTP (Amersham) using Megaprimer labelling 
kit (Amersham). The autoradiograph of the membrane was exposed for 5 days. 
2.3.2 Characterisation of the chicken TRH-R 
Cell culture and transfection 
COS-I cells were grown at 37 °C in an humidified atmosphere containing 5 % 
CO2. One to two days before transfection, the COS-1 cells were harvested with trypsin, 
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and plated out at 0.6 - 0.8 x 105 cells/ 25mm well for inositol phosphate (IP) and cyclic 
AMP (cAMP) formation assays. The cells were transfected for 3.5 h with the chicken 
TRH-R cDNA, or the mouse TRH-R cDNA, which were subcloned into the pcDNA 
I/Amp vector (Invitrogen Corp., CA), using a modification of the DEAE-dextran method 
(Cullen, 1987). For IP formation assay, the cells were labelled with myo-[3H]-inositol 
(lµCi/ml , Amersham) in Dulbecco's modified Eagle's medium (DMEM supplemented by 
2 % fetal calf serum and penicillin/ streptomycin) for 16 h to 22 h in a 37 °C incubator (5 
% CO2), 48 h after transfection. 
Inositol phosphate (IP) formation assay 
IP formation was measured as previously described (Millar et al., 1995). Briefly, 
the myo-[3H]-inositol labelled cells were washed twice with buffer A (140 mM NaCl, 
4mM KCl, 20mM HEPES, 0.1% BSA, 8 mM D-glucose, pH 7.4, lmM CaC12 and 1 mM 
MgCl2 ) at 37 °C for 5 min. Then, the cells were incubated with buffer A (containing 10 
mM LiCl) in the presence or absence of TRH analogues for 1 hat 37 °C. All experiments 
were performed in duplicate and were repeated at least twice. 
cAMP formation assay 
The cells were washed twice with buffer A and incubated with the buffer 
(containing 10 mM LiCl) in the presence or absence of TRH ( 1 nM - 10 µM) for 60 min 
with 0.25 mM IBMX (a cyclic nucleotide phosphodiesterase inhibitor) at 37 °C, 48 h after 
transfection. COS-I cells, transfected with human J3radrenergic receptor cDNA, w~re 
incubated with 1 µM of epinephrine (in the presence of 0.25 mM IBMX) as a positive 
control. cAMP was extracted using 4 mM EDT A, and measured by radioimmunoassay 
(Amersham kit, TKR 342). Individual experiments were repeated twice in duplicate. 
Receptor binding assay 
The receptor binding of the chicken TRH-R was carried out at Prof. Gershengorn' s 
lab, and was done by Dr. H. Ho (Dept. of Medicine, Cornell University Medical College, 
New York, USA). 
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Data analysis 
The values of Ki (receptor affinity), and EC50 (IP formation) were estimated by 
non-linear regression analysis using the PRISM program (GraphPad Inc.). Dose-response 
curves ( each data point is a mean of all experiments) of IP and cAMP formation assays 
and competition binding assay were drawn using the same program. 
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2.4RESULTS 
Summary of the work in cloning chicken TRH-R cDNA 
The work in cloning the chicken TRH-R gene is summarised in Fig. 2.7. In order 
to elucidate the multiple steps of the cloning work, methods which were applied to the 
work are presented step by step in Figure 2.7. The result of each step is included to 
indicate the problem which I faced at the time, and the result became a useful tool to 
tackle the next problem. 
Firstly, the cDNA library of the chicken pituitary gland was constructed and it was 
a good library. Three chicken TRH-R cDNA clones (Trun-1, -2, and -3) were isolated 
from the cDNA library of the chicken pituitary gland, using a mouse TRH receptor cDNA 
probe. They were identified by sequencing and they all contained a stop codon (TAA) 
within the putative intra-cellular (IL) loop 3. Five primers, CHl to CH5, were designed. 
In order to get more 3'-end sequences of the receptor, two strategies were used: 3'-
RACE (3'-end rapid amplification) and PCR (polymerase chain reaction). In the first step, 
3'-RACE was applied to amplify the 3'-untranslated region of the receptor from chicken 
pituitary cDNAs using a gene specific primer (CH2) and an oligo ( dT) primer/adaptorB. 
The PCR-products were subcloned and were identified by sequencing. However, the three 
clones that were analysed all had the same stop codon in the putative IL 3, and a poly 
(Aso) tail. In the second approach, the cDNA library was screened with a chicken TRH-R 
probe, which extended from EL 2 to TM 6. This probe was isolated using a PCR strategy 
with a chicken primer (CHI) and a primer designed against TM 6 of the mouse TRH-R. 
None of the 9 clones, which were analysed by restriction enzyme mapping and partial 
sequencing, was a full-length receptor. They were all incomplete receptors, but contained 
an entire 3' un-translated region and a poly(At tail. Therefore, one primer (CH6), which 
was located at the 3' un-translated region just after the stop codon, was designed 
according to the sequence data derived from the incomplete cDNA clone. 
A full-length chicken TRH-R cDNA was amplified by PCR with a pair of gene 
specific primers (CH5 and CH6), which flanked the entire coding region of the chicken 
TRH-R. However, various mutated amino acids were verified in full-length cDNA clones, 
as compared to amino acid sequences of the cDNA clones ( eg. Trun-1 and Trun-4 ), which 
were isolated by screening the cDNA library. Therefore, a "wild type" chicken TRH-R 
cDNA was constructed by ligating two parts of the chicken receptor gene from Trun-3 
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and Trun-4 clones. The detailed infonnation for each step will be addressed in the 
following sections. 
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1. Constructing a cDNA library from 
chicken pituitary glands 
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The cDNA library of the chicken pituitary gland 
The cDNA libracy of the chicken pituitary was titered at 2x106 pfu before 
amplification, and l.2x1010 pfu/ml phage lysate after amplification. The ratio of the cDNAs 
inserted into the Uni-ZAP XR A. vector arms, at the primacy construction, was more than 100 
white:blue ratio selected by IPTG/X-Gal. White plaques indicate that the vector contains 
cDNA; blue ones have no insertion. After cDNA amplification, the white:blue ratio was 30. 
In addition, the chicken libracy contained 1.4% of J>-actin recombinants identified by 
screening 105 plaques hybridised with a 32P-labelled mouse J3-actin cDNA. ( J3-actin is highly 
expressed and is usually used as an "internal control". If one libracy contains more than 1 % 
of J3-actin, the libracy is qualified as a good libracy.) 
The chicken TRH-R cDNA clones 
Twelve truncated chicken TRH-R cDNAs were isolated from a cDNA libraiy of 
the chicken pituitary gland by using the mouse TRH-R or the chicken TRH-R probes 
(Fig. 2.8). Trun-1,-2, and -3 (size: about 1.4 kb), which were cloned using the full-length 
mouse THR-R cDNA as a probe, were identified by sequencing in both directions (Fig·. 
2.8, panel A). The nucleotide sequence data of the three clones revealed that they all had a 
stop codon (TAA) at the nucleotide +1006 (downstream) that resulted in a receptor that 
prematurely terminates in the putative IL 3. The downstream region, from a point 20 
amino acid sequences before the stop codon, had no homology with the mammalian TRH 
receptor and was termed the divergent region. The consensus 5'-end sequence of the 
exon-intron junction, AGgtag , was found at the point of homology divergence. Trun-2 
and -3 were identical. However, Trun-1 showed slightly different nucleotide sequences 
from the other two clones in its lack of 72 bp at 13 nucleotides (-13) upstream from the 
start of the open reading frame ( + 1 ). Five primers, CHI to CHS, were designed (Fig. 2.8, 
panel A). 
In order to obtain the 3'-end sequence data of the chicken TRH-R gene, 3'-RACE 
was applied to amplify up the 3 '-untranslated region of the receptor gene with primers 
CH2 and adaptorB. Three of the cloned PCR-products were identified by sequencing and 
they showed that they all were comprised of a premature stop codon at the nucleotide 
+ 1006 and a poly(A)so tail. Therefore, another strategy (PCR) was used to amplify the EL 
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2 - TM 6 coding region of the chicken TRH-R gene with a gene specific primer CHI and a 
mouse 
Fig. 2.8 A diagram illustrating the different types of cTRH-R cDNAs isolated from the 
cDNA library of the chicken pituitary gland. (A) Three truncated clones were 
isolated by screening the chicken cDNA library hybridised with a
32P-labelled 
mouse TRH-R cDNA. (B) Nine truncated clones were isolated by using a
32P-
labelled chicken TRH-R cDNA probe. (C) The constructed full-length chicken 
THR-R. Three restriction enzyme sites are indicated. A Hind III restriction site is 
in the pSK + vector and Ssp I and BamH I sites are in the chicken TRH-R. ORF: 
open reading frame; M: methionine; CHl- 6: primers; TM: transmembrane ; *: 
stop codon;"-" and "+" : up- and down-stream of the open reading frame(+ 1); 
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T VI VII BamHl 
* 
TRH-R primer. This PCR-product was subcloned into pMOS-Blue vector (Amersham) and 
verified by sequencing. This PCR clone was used to screen the cDNA library of the 
chicken pituitary gland. 25 positive clones were isolated. Of the 25 clones, 9 clones (Trun-
4 to Trun-12, sized: 3.8 Kb - 4.1 Kb) were identified by partial sequencing and by 
restriction enzyme mapping (Fig. 2.8, panel B). They appeared to be two types of 
incomplete cDNA clones, encoding either from half of TM 4, or from half of IL 3, to the 
poly(At tail. Interestingly, they all contained a methionine at the beginning of the clones. 
Since these incomplete forms all contained a large 3'-untranslated region(> 3 Kb), they 
might result from a limited efficiency of the Reverse Transcriptase. Based on the nucleotide 
sequence data of the 3'-untranslated region, a primer (CH6) was designed against the 
region following after the stop codon. 
PCR was applied to amplify the full-length TRH-R cDNA with a pair of primers, 
CH5 and CH6, from the chicken pituitary cDNA. The PCR-products were subcloned into 
the pMOS-Blue vector. Six of the full-length TRH receptor cDNA clones were verified by 
sequencing, and they all contained randomly mutated sequences as compared to those of 
the cDNA clones, which were isolated from the chicken cDNA library. Therefore, a full 
length chicken TRH receptor cDNA was constructed by ligating two fragments from 
truncated clones. The Hind IWSsp I fragment from Trun-3, was ligated to the Ssp I/ BamH 
I fragment from Trun-4, and cloned into the pcDNA I/Amp vector digested with Hind 
IWBamH I restriction enzymes (Fig. 2.8, panel C). 
The chicken TRH receptor 
The constructed full-length chicken TRH-R (size about 1.2 Kb) showed 76 and 84 
% identity to the nucleotide and amino acid sequences of the mouse TRH-R, respectively 
(Fig. 2.9A and B). The nucleotide sequences of the chicken TRH-R has been submitted to 
the EMBL and its accession number is Y18244. Completely conserved regions in both 
receptors are IL I and 2, EL 3, TM 2, and TM 7. The divergent parts are the extracellular 
N-terminus, the middle part and the C-terminal part of IL 3 ( if the loop is divided into 
three parts), as these parts only share 55, 53, and 60 % homology, respectively. There are 
two additional amino acids (Thr23 and Ala24) in the chicken TRH-R. The chicken TRH-R 
contains two potential sites for N-linked glycosylation {Asn-X-Ser/Thr) in the N-terminus, 
also conserved in the mouse counterpart. 
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A) 
atg gag aat ggc aca ggc gac gag cag aac cat act ggg ctg ctg ctg tea age cag 
M E N G T G D E Q N B T G L L L s s Q 
gag ttc gtt aca get gaa tac caa gtg gtt ace ate etc ttg gtc etc etc ate tgt 
E F V T A E y Q V V T I L L V L L I C 
gga ctg ggc ate gtg ggc aac ate atg gtg gtc ttg gtg gtc etc aga ace aaa cac 
G L G I V G N I M V V L V V L R T IC B 
atg aga act CCC act aac tgc tat ctg gtt agt ctg get gtg gca gat etc atg gtg 
M R T p T N C y L V s L A V A D L M V 
ctt gtg get gca gga eta CCC aat ate aca gaa agt ctg tac aaa tee tgg gtc tat 
L V A A G L p N I T B s L y IC s 1f V y 
ggc tat gtg ggg tgc etc tgc ate act tat etc cag tac eta ggg ate aat get tct 
G y V G C L C I T y L Q y L G I N A s 
tct ttt tee ate act get ttc ace ate gag aga tat ata get ate tgc cac cca ate 
s F s I 'l' A F T I E R y I A I C B p I 
aaa get caa ttc eta tgc aca ttt tea aga get aag aag ate att att ttt gtc tgg 
K A Q F L C T F s R A IC K I I I F V w 
tct ttc gee tea gta tac tgt atg etc tgg ttt ttc eta tta gat etc aat ata gca 
s F A s V y C M L w F F L L D L N I A 
gtc tac aaa gac act acg gtt gtg tct tgt gga tac aag gtg tee agg age tat tac 
V y K D T T V V s C G y K V s R s y y 
tct cct ate tac atg atg gac ttc gga ata ttt tat gtt ttg cca atg gta ttg gca 
s p I y M M D F G I I' y V L p M V L A 
act gtc etc tat ggc ctg att get aga ata ctg ttc ctg aat CCC ate cct tcg gac 
T V L y G L I A R I L F L N p I p s D 
cca aaa gaa aac tct aac acg tgg aaa aat gac atg get caa caa aac aag act gtg 
p IC E N s N T w IC N D M A Q Q N K T V 
aat tee aag atg act aac aag agt ttc aat age act att get tct aga aga cag gtt 
N s K M T N IC s F N s T I A s R R Q V 
ace aag atg ttg get gtg gtg gta gtc etc ttt gca ttt ctg tgg atg CCC tat cga 
T K M L A V V V V L I' A F L w M p y R 
aca ctg gtg gtt gtc aat tee ttt etc tee agt CCC ttc caa gaa aac tgg ttc ctg 
'1' L V V V N s F L s s p F Q E N w F L 
eta ttt tgc aga ate tgt att tat tta aat agt gee ate aat cct gta att tac aat 
L F C R I C I y L N s A I N p V I y N 
etc atg tee cag aaa ttc aga gca gee ttc agg aaa etc tgc aac tgc cat eta aaa 
L M s Q K F R A A F R K L C N C B L K 
egg gac aag aaa cct gee aat tac agt gtg gee eta aat tat aat gtc ate aaa gag 
R D K !C p A N y s V A L N y N V I K E 
tct gat cac ttc age agt gaa ata gaa gat att act gtc ace aat ace tat ttg tee 
s D B F s s E I E D I T V 'l' N T y L s 
tct gca aaa aca tee att ggt gac aca tgt ttg tct tct gag gee tga 
s A K 'l' s I G D T C L s s E A * 
Fig. 2.9 (A) The nucleotide and amino acid sequences of the chicken TRH-
R. (B) Alignment of the deduced amino acid sequences of the 
chicken TRH-R (ch) and the mouse TRH-R (m). Putative 
transmembrane (TM) helix.es for the chicken TRH receptor were 
assigned based on those of the mouse receptor (Gershengom et al., 
1996). Identical residues between both species are shown in red 
letters. IL: intracellular loop, EL: extracellular loop," ... ": space,"* 
": stop codon, and the numbers: the positions of amino acids (top 







101 TM III 150 
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However, there is an additional glycosylation site in the EL 2 of the mammalian 
receptors, but it is absent in the chicken receptor (Fig. 2.9). The primary structural details 
of the chicken receptor will be addressed in the discussion section. 
Identification of the divergent region of the truncated chicken TRH-R 
In order to analyse the divergent region of the Trun-1, -2, and -3 clones, the 
chicken TRH-R genomic clones were isolated from 7.5xl0
5 plaques of a chicken genomic 
library by hybridising with a 32P-labelled Trun-3 cDNA. Two positive clones, YSl and 
YS2, were isolated after tertiary screening (Fig. 2.10, 2.11, and 2.12). The position of the 
divergent region of the Trun-1, -2, and -3 clones in the TRH-R gene, was identified by 
analysing the TRH-R genomic clone (YSl) (Fig. 2.13) using Southern blot (Fig. 2.14, 
panel A) and PCR analysis (Fig. 2.14, panel B). 
Nucleotide sequence analysis of the truncated chicken TRH-Rs (Trun-1, -2 and -3 
) identified the presence of an EcoR I site and a Xba I site, proceeding the divergent 
region. The Trun-3 clone (subcloned into the pSK- vector digested with Hind Ill and 
BamH I) was used to make two probes (A and B) by digesting with Pst I, Xba I, and 
BamH I (Fig. 2.13). Probe A contained the 5'un-translated region to IL 3 of the receptor, 
and probe B was the divergent region. The Southern blot analysis revealed that the YS 1 
contained the probe A region, i.e. exon 1 (in the 1.2 Kb EcoR I fragment), and the probe 
B region in the 1.5 Kb EcoR I/Hind III or EcoR I/ BamH I fragments (Fig. 2.14, panel A). 
The exon 1 and the divergent region were located in an 8.0 Kb Hind III ( or BamH I) 
digest which retained a 5.3 Kb fragment of the A charon 4A vector (Fig. 2.13, bottom 
panel; Fig. 2.14, panel A); that is, the band of the chicken receptor gene that was 
hybridised with the probes A and B had a size of 2. 7 Kb. It indicated that exon 1 adjoined 
the divergent region. 
This was re-confirmed by PCR using the cDNA and genomic clones as templates. 
Same size PCR-products from the templates, Trun-3 and genomic clones, were amplified 
with two pairs of primers (Fig. 2.14, panel B), whereas the negative control (H20) was 
blank. In addition, there were no PCR-products shown in the Trun-4 cDNA clone (a 
negative control), in which the intron had been spliced out. The finding suggested that the 
divergent region of Trun-3 is part of an intron (Fig. 2.13). 
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Fig. 2.10 One of two positives (shown in duplicate), YSJ (the chicken genomic 
clone), hybridised with d 2P-labelled Trun-3 in 7.5xHI plaques 
primary screening. The autoradiographs were exposed for 4 days. 
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Fig. 2.11 Ample positives, hybridised with d2P-labelled Trun-3 in the 
secondary screening ( duplicate membranes) of the YSJ 
clone. The autoradiographs were exposed for 5 hr . 
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Fig. 2.12 Ample positives, hybridised with d 2 P-labelled Trun-3 in 
the tertiary screening (duplicate membranes) of the YSJ 
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Fig. 2.13 Schematic representation of the chicken TRH-R genomic and 
truncated cDNA clones. The divergent region of the truncated 
cDNA was verified as an intron by Southern blot analysis and PCR 
(shown in Fig. 2. 14). The intron follows on from exon 1 where the 
consensus 5'-end sequence of the exon-intronjunction (AGgtag) is 
shown. Exon 1 encodes the 5'-untranslated region through most of 
intracellular loop 3. The probes A and B, and 4 primers, which are 
indicated in Fig. 2.14, are shown at the corresponding regions of the 
cDNA clone. ORF: open reading frame; TM: transmembrane; "-" or 
"+": up-or down-stream of the open reading frame(+ 1); numbers: 
a positional number of nucleotide sequence. "// ": region not shown. 
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Fig. 2.14 Identification of the divergent region of the truncated chicken TRH-R. 
(A) Southern blot analysis of the chicken TRH receptor genomic clone (YS1 clone in 
the A charon 4A vector digested with EcoR I) digested with EcoR I (E), Xba I (X), 
Hind III (H), and BamH I (B) or combinations, and hybridised with a
32P-labelled 
probes (A and B) (shown in Fig. 2.13). 
(B) Polymerase chain reaction was applied to identify the divergent region using the 
gene specific primers of the chicken TRH-R (shown in Fig. 2.13). The 0.5 and 
0.25 Kb of PCR-products were amplified with two pairs of primers, CHI & CH4 
and CH2 & CH3, respectively, from two templates, which are Trun-3 clone (lane 
1) and genomic clone (lane 2), while the negative controls, Trun-4 clone (lane 3), 
and water (lane 4) are blank. Marker presents in lane 5. 
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The expression ofthe chicken TRH-R gene in pituitary glands 
The expression of the chicken TRH-R gene was detected by Northern blot, 
hybridised with a.32P-labelled full-length chicken TRH receptor cDNA. Three mRNA 
transcripts of the chicken receptor (sizes at about 5, 3.2, and 1.4 kb), were detected in the 
chicken pituitary, whereas no signal was detected in the negative control (the sheep 
pituitary) (Fig. 2.15). The major species of the transcript was sized at 5 kb. 
Fig. 2.15 The Northern blot analysis of the chicken TRH-R gene 
in the pituitary gland. Three mRNA transcripts of the 
chicken receptor, 5 kb, 3.2 kb, and 1.4 kb, were detected 
in the chicken pituitary gland ( chicken), by autoradiograph, 





Pharmacologi.cal properties ofthe chicken TRH-R 
To characterise the constructed full-length chicken TRH-R, the receptor binding 
and IP formation assays were performed in COS-I cells expressing the chicken TRH-R or 
the mouse TRH-R (as a comparison). The assays were determined by employing several 
TRH analogues, which have different substitutions at the residues 1, 2, and 3 of TRH, 
since it has been proposed that the side chains of all three amino acid residues of TRH are 
involved in binding to TRH-R. 
In binding experiments that were completed at Prof Gershengorn's lab (Cornell 
U. ), the affinity (Ki = 8.1 nM) of TRH to the chicken receptor was 500-, 1500-, and 1850-
fold higher than that of Desaza
1TRH, Val2TRH, and Pyr
3TRH, respectively. The mouse 
receptor showed a similar pattern of decreased affinity for these analogues. There was no 
significant difference in affinity, between chicken and mouse receptors, for any analog. 
The EC50 ( 10.2 nM) for stimulation of IP formation by TRH in the chicken receptor was 
about 40-fold lower than those ofDesaza
1TRH and Phe2TRH, and IO-fold higher than that 
of MeTRH (Fig. 2.16; Table 2.3). The mouse receptor displayed a similar pattern of 
potency for stimulating IP formation by these analogues. There was no significant 
difference in this pharmacological aspect between the chicken and mouse receptors. Figure 
2.17 shows that there is no cAMP formation in the presence of various doses of TRH (up 
to 10 µM) in COS- I cells transfected with the chicken or the mouse TRH-R cDNAs. 
However, the positive control (COS-I cell transfected with J3radrenergic receptor cDNA) 
showed cAMP formation in the presence of 1 µM epinephrine. 
In order to test whether the truncated receptors were functional, IP formation 
assays were performed to evaluate their responses to TRH. The truncated isoforms were 
expressed in COS-I cells alone, or co-expressed in the cells [e.g. Trun-3 and -4, or Trun-3 
and the constructed full-length receptor (wild type)]. They were characterised by 
measuring IP formation in the presence of various doses of TRH. No truncated isoforms 
(neither individual nor co-transfection) exhibited IP formation (Fig. 2.18). Additionally, 
there was no significant difference in the EC50 values in COS-I cells expressing the wild 
type receptor, alone or with the Trun-3 receptor. This finding indicated that the truncated 
receptor did not exhibit a negative effect on the wild type receptor. 
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Table 2.3 Receptor binding affinity and stimulation of inositol phosphate (IP) 
formation by TRH analogues in COS-I cells expressing the chicken or mouse 
TRH-Rs 






TRH 8.1 11 10.2 11.1 
(4.3 -1st (7.9 - 16) (5.2 - 20.1) (7.9 - 15.5) 
Desaza1TRH 4200 4800 453.3 341.6 
(2200-8000) (1900-12000) (251-817) (299-494) 
Phe2TRH ND ND 425.5 158.7 
(133-536) (88.4-285) 
MeTRH ND ND 0.93 1.91 
(0.5 - 1.6) (0.9 -3.8) 
VaI2TRH 12000 5600 ND ND 
( 6800-22000) (3800-8400) 
Pyr3TRH 15000 14000 ND ND 
(7700-28000) (8600-23000) 
0
: The data were obtained from Prof. Gershengom's lab. 
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Fig. 2.17 Lack of stimulation of cAMP formation by TRH in COS-1 
cells expressing chicken TRH-R (cTRH-R) or mouse TRH-R 
(mTRH-R). The COS-1 cells expressing J3radrenergic receptor 
(J3i-AR) were stimulated with 1 µM epinephrine as a positive 
control. The levels of cAMP were measured in the presence of 
0 .25 mM IBMX. Each curve is representative of two 
experiments in duplicate. 
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Fig. 2.18 Dose-response curves for inositol phosphate formation stimulated 
by TRH in COS-1 cells expressing the chicken TRH-R isoforms, 
alone, or co-expression. W: the constructed wild type receptor; 
Trun-3&-4: co-transfecting the Trun-3 and-4 clones; Trun-3&W: 
co-transfecting the Trun-3 and the wild type receptor. 
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2.5 DISCUSSION 
The deduced amino acid sequence of the chicken TRH-R exhibits about 80 % 
identity to the mammalian counterparts ( excluding two isoforms of rodents). It is of interest 
to note that the related chicken gonadotrophin-releasing hormone (GnRH) receptor shares 
only 40 % identity with mammalian GnRH-Rs (Troskie et al., 1997). It appears that there 
has been considerable evolutionary constraint on the TRH-R structure for interaction with 
the smaller ligand. This is consistent with the finding that there is high conservation of 
primary amino acid sequences between receptors for small ligands amongst different 
species in the biogenic amino receptors (Cascieri et al., 1995). 
Using a combination of mutagenesis and computer simulation studies, a putative 
binding pocket of mouse TRH-R has been identified (Perlman et al., 1992). All of these 
candidate ligand interacting sites are conserved in the chicken receptor. It has been 
proposed that the binding of TRH to its receptor involves hydrogen bonding interactions 
and hydrophobic interactions rather than ionic interactions. The putative binding pocket 
includes Tyr106 (Tyr108 in the chicken receptor) in TM3, whose OH group is suggested to 
form an H bond with the C=O of the pyroGlu residue of TRH, because the substitution of 
Tyr106 with Phe106 (abolishing OH group) impaired the receptor affinity for TRH by 
100,000-fold (Perlman et al., 1994a). Using the same approach, the Asn
110 residue (Asn112 
in the chicken receptor) was shown to form an H bond with the NH group of pyroGlu of 
TRH at its C=O group (Perlman et al., 1994b). Following computer simulation studies, a 
three-dimensional model of the TRH-R was developed (Gershengom et al., 1996). It 
identified that the Tyr2
82 (Tyr284 in chicken) in TM 6 forms a hydrophobic interaction with 
the imidazole of the His residue of TRH. In addition, the Arg
306 (Arg308 in chicken) in TM 
7 interacts with the ProNH2 of TRH. Other residues have been identified (e.g. Gln
105 and 
Tyr282 ) that are involved in inter-helical H-bonding interactions but do not directly interact 
with TRH (Perlman et al., 1994b). These residues are all conserved in the chicken receptor. 
It has been suggested that TRH binds to the TRH-R by interacting initially with residues in 
ELs and is then guided into the TM binding pocket (Perlman et al., in press). Asn
289 is one 
of the EL interacting sites, and it is also present at an homologous position in the chicken 
receptor. 
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Apart from the binding pocket, the chicken receptor is likely to share similarities in 
the mechanism of receptor activation with the mammalian receptors. For example, two 
residues, Asp71 in TM 2 and Arg
283 in TM 6, which play a role in G-protein coupling in the 
mouse receptor (Perlman et al. , 1992, Perlman et al., 1995) are conserved in the chicken 
receptor. On the other hand, the chicken receptor displays some features that are different 
from the mammalian homologues. The chicken receptor lacks a potential N-glycosylation 
site in EL 2, which is present in the mammalian receptors (Asn
167 
) . It has been shown that 
glycosylation may play a role in receptor expression or stability (Davidson et al., 1995). 
Additionally, a difference in the distribution of putative phosphorylation sites (Kennelly 
and Krebs, 1991) exists in the chicken and mammalian receptors. The chicken receptor 
contains 4 additional putative phosphorylation sites in the C-terminal part of IL 3, whereas 
the mammalian receptors consist of four extra putative phosphorylation sites in the C-
terminal tail. Phosphorylation may play a part in desensitisation of receptors. The chicken 
receptor exhibits a difference in down-regulation from that of the mammalian counterpart 
(Harvey et al. , 1990b ). Down-regulation of the chicken TRH-R occurs within 30 min after 
administration of TRH and is maintained for at least 60 min in in vivo and in vitro studies. 
On the contrary, the down-regulation of the mammalian receptors occurs after several days 
of TRH challenge in vivo (Gershengorn et al., 1978; Simasko and Horita, 1985) or after 
12-24 h of TRH treatment in vitro (Hinkle and Tashjian, 1975). It remains to be further 
investigated whether or not the putative phosphorylation sites are involved in the 
regulation of receptor down-regulation. 
The chicken TRH-R, like mammalian TRH-Rs, has retained several amino acids 
which are highly conserved in GPCRs. These include TMr Asp
73 and TMrAsn318 (Asp71
 
and Asn316 in the mammalian receptors), in which the Asp residue is involved in receptor 
activation in many GPCRs (Baldwin, 1994) including the mouse receptor (Perlman et al. , 
1992). The highly conserved Cys residues at 100 and 181 ( 98 and 179 in mammals) have 
been shown to form a disulphide bond between EL 1 and EL 2 to stabilise the structure of 
functional receptor in GPCRs (Baldwin, 1994) and the mouse TRH-R (Perlman et al., 
1995). Two other Cys residues, Cys
337 and Cys339 ( 335 and 337 in the mammalian 
receptors) are present in the C-terminal tail. Homologous Cys residues have been shown to 
be palmitoylated and may anchor the tail in the plasma membrane which is proposed to be 
important for interactions with G protein (Ovchinnikov et al., 1988; O'Dowd et al., 1989). 
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In contrast, the Cys residues in the mammalian TRH-R are not necessary for G-protein 
coupling, but may play a role in restraining the receptor in an inactive conformation that is 
optimal for rapid internalisation of the receptor (Nussenzveig et al. , 1993a) because a 
truncation mutation (C335Stop) at this locus of the mouse TRH-R exhibits constitutive (or 
agonist-independent) activity (Matus-Leibovitch et al., 1995). The highly conserved Asp-
Arg-Tyr (DRY) motif at the C-terminal part of TM 3, which is involved in G-protein 
coupling and receptor internalisation (Arora et al., 1997), is present as ER Y in the chicken 
and mammalian receptors as in several other receptors. A substitution of the Asp residue 
with Glu (E) in a mammalian GnRH-R results in increasing binding affinity, activation, 
and the rate of internalisation (Arora et al., 1995). Following the DRY motif, the 
XXI/VXXPL/1 motif, in which the Pro and Leu residues have been established to play a 
role in G-protein coupling (Arora et al. , 1995; Sealfon et al. , 1997), is also conserved in 
the chicken and mammalian receptors. Moreover, Asn
43 (TM 1), Trp150 (TM 4), Pro
203 
(TM 5), FXXXWXP motif (TM 6), and NPXXY motif (TM 7), which are conserved GPCR 
residues present in the mammalian TRH-Rs, are also conserved in the chicken TRH-R. 
The pharmacological properties of the chicken receptor were evaluated by applying 
different TRH (pGlu-His-Pro-NH2 ) analogues, in which residues 1, 2, and 3 were 
substituted individually with different amino acids, to measure their receptor binding 
activities and/ or G-protein coupling. These experiments confirmed that the side chains of 
all three amino acid residues of TRH are involved in receptor binding. Desaza
1 TRH, in 
which the NH ring of pyroGlu was substituted by a CH2 group, exhibits an approximately 
500-fold decrease in affinity for the chicken and mouse receptors. Modifications in the 
histidine residue of TRH can lead to marked effects on the binding affinity that in tum 
affects the potency for IP formation and for secretion of thyrotrophin (TSH). One of these 
TRH analogues, Vai2 TRH, in which the histidine residue of TRH was replaced by valine, 
showed an over 500-fold decrease in affinity for the chicken and mouse receptors. A 
portion of the decrease may be due to the loss of a stacking interaction between the ligand 
and receptor, because it was postulated that the imidazole of the His residue forms 
hydrophobic interactions with a pocket formed by Tyr2
82
, Tyr188 , Tyr192, Phe1%, and Phe199 
(Gershengorn et al. , 1996; Han and Tashjian, 1995). This may also explain why when 
histidine was substituted with a strongly hydrophobic phenylalanine there was less than an 
100-fold decrease in the binding affinity (Perlman et al. , 1994b) and in stimulating IP 
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fonnation in this study. In addition, a portion of the decrease in affinity of Vat2 TRH or 
Phe2 TRH may result from the loss of an H bond interaction, because residue Ser
113 of the 
receptor was suggested to fonn an H bond with the histidine (Gershengorn et al., 1996). 
Furthennore, the binding affinity of the chicken receptor for Pyr
3 TRH, in which the 
ProNH2 residue is substituted by a pyrrolidine ring, is 1,800-fold lower than for TRH, as 
with the mouse receptor. It was suggested that the C=O group of Pro residue of TRH fonns 
an H bond with the guanidino group of Arg
306 residue in the receptor. 
It has been suggested that the adenylyl cyclase-cyclic adenosine 3' ,5' -
monophosphate ( cAMP) pathway plays a role as a secondary messenger in TRH-induced 
physiological functions, in addition to the phospholipase C-inositol 1,4,5-trisphosphate -
1,2-diacylglycerol -Ca++ pathway. Evidence has been presented that cAMP is involved in 
TRH-stimulated prolactin secretion in rat pituitary tumour cell line (GH cells) (Gautvik et 
al., 1983), and may participate in TRH-induced growth honnone release in chicken 
somatotrophs (Perez et al. , 1989). However, we demonstrated here that TRH does not 
elevate cAMP levels in the COS-1 cells transiently expressing chicken or mouse TRH-Rs. 
The result is consistent with the finding that TRH did not stimulate cAMP fonnation in the 
mouse TRH-R expressed in 5 different cell types (Heinflink et al., 1994). 
The truncated isofonns of the chicken TRH-R cDNA that we isolated are not 
functional receptors. Trun-1 , -2, and -3 clones that contain a premature stop codon (TAA) 
in IL 3, are due to the retention of an un-spliced intron. Intriguingly, these truncated 
receptor clones were shown by PCR and sequencing studies to contain a poly (A)49 tail and 
an AA T AAA consensus sequence of the polyadenylation signal site upstream of the tail 
( unpublished data). Additionally, the sizes of these truncated cDNA clones ( about 1. 4 kb) 
are correlated with one of the mRNA transcripts of the chicken receptor expressed in the 
pituitary gland. This indicates that these receptor are fully processed mRNA transcripts 
and are not cloning artifacts. It is noteworthy that the human TRH-R gene also contains a 
large intron (25 kb) at an homologous position (Iwasaki, et al. , 1996). In addition, two 
alternatively spliced fonns of TRH-R have each been cloned, from mouse (Duthie et al. , 
1993b) and from rat (De La Pena et al., 1992). These isofonns are characterised by 
different amino acid sequences in their respective C-tenninal tails and are functional 
receptors. The isofonns of the rat receptor are produced by alternative splicing of a 
retained intron, whereas those of the mouse receptor may be fonned by alternative splicing 
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of two exons. Other truncated fonns of the cTRH-R , Trun-4 to Trun-12, might be due to 
inefficiency of the reverse transcriptase (M-MuL VRT), which was used in first strand 
cDNA synthesis, because these cDNA clones all contain a large 3' un-translated region (> 
3kb). 
In conclusion, we have cloned a cDNA for the chicken TRH-R and found it to be 
highly homologous and pharmacologically indistinguishable from the previously cloned 
receptors from mouse, rat and human species. This degree of evolutionary conservation is 
unusual and may be related to the small number of contacts that must be maintained 




Cloning and Characterisation of - chicken GnRH Receptor (GnRH-R) 
3.1 Abstract 
3.2 Introduction 





The chicken GnRH-R cDNA has been cloned from the chicken pituitary gland. As 
compared to the cloned mammalian receptors, the clucken receptor consists of some 
unique features : a C-terminal tail containing 56 amino acids, a longer N-terminus (7 amino 
acids longer), a short intracellular loop 1 (only 6 amino acids), Asp (D) residues in TM 2 
and TM 7 (N/D in the mammalian receptors and DIN in most of GPCRs), an Asp-Arg-His 
(DRH) motif at the intracellular junction of TM 3 (DRY in the mammalian receptor), and 
two additional Cys (Cys2 and Cys29) in the N-terminal tail. Moreover, the chicken GnRH-R 
only shares about 40 % identity of amino acid sequences with its mammalian counterparts. 
The N-terminus and intracellular loops are more divergent (about 20 % identity), while 
having a comparatively higher level of amino acid sequence identity within the 
transmembrane domains and the extracellular loops. However, the putative binding sites 
Asn102, Lys 121 , and Glu30 1 for GnRH that have been proposed in the mouse GnRH-R, are all 
conserved in the chicken receptor. Additionally, two Cys residues in EL 1 and EL 2 that 
are predicted to form a disulphide bridge, and the putative glycosylation sites, are found in 
homologous residues in the chicken receptor. 
Given the strikingly different structural features from the mammalian receptors, the 
chicken receptor possesses some unique pharmacological properties. For example, the 
chicken receptor exhibits over 10-fold higher affinity for cGnRH II and [D-Arg6]GnRH II 
than for cGnRH I and mGnRH, whereas the mammalian receptors prefer mGnRH to 
cGnRH I, II, and [D-Arg6]GnRH II. Moreover, of six mammalian antagonists studied, three 
antagonists (135-18, 135-25, and 26) display an agonistic behaviour for the chicken 
receptor, while they act as full antagonists in the mammals. 
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3.2 INTRODUCTION 
As covered in the general introduction ( chapter 1 ), the hypothalamic decapeptide 
GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), plays a vital role in regulating 
the hypothalamo-pituitary-gonad reproductive axis. To date, twelve structural forms of 
GnRH have been identified in vertebrates. Chicken GnRH I (cGnRH I: [Gln
8]-GnRH) and II 
(cGnRH II: [His5, Trp7, Tyr8]-GnRH) have been isolated from the chicken hypothalamus and 
brain (King et al., 1982; Miyamoto et al., 1984). The distribution of the two hormones is not 
the same. One of the most important differences is that immunoreactive (ir)-cGnRH I fibres 
have been detected in the median eminence, but not ir-cGnRH II fibres (Mikami et al., 
1988). Moreover, the amount of cGnRH I in the median eminence of the chicken is regulated 
by the physiological reproductive state, however, no cGnRH II is detected in this region 
(Sharp et al., 1990). These findings suggest that cGnRH II may not be important for the 
pituitary-gonad axis, but it may serve a neurotransmitter or neuromodulator role. 
It is well established that GnRH exerts its physiological role, firstly, via binding to its 
specific receptor (GnRH-R) in the membrane of gonadotrophs; then, coupling to Gq and/or 
0 11 which in turn promotes secondary messengers (DAG and IP3) signalling cascade (Hsieh 
et al., 1992). The GnRH-R, a member of the G-protein coupled receptor (GPCR) family, has 
been cloned from several mammalian species and one non-mammalian class: mouse 
(Tsutsumi et al., 1992), rat (Eidne et al., 1992), human (Chi et al., 1993), sheep (llling et al., 
1993), cattle ( Kakar et al., 1993), pig (Weesner et al., 1994), and catfish (Tensen et al., 
1997). As compared to other GPCRs, the mammalian GnRH-Rs possess several unusual or 
unique features. These include a complete absence of intracellular C-terminal tail, the change 
of the highly conserved Asp-Arg-Tyr (DRY) motif to Asp-Arg-Ser (DRS) at the end of the 
transmembrane (TM) domain 3, and the reciprocal exchange of the conserved TM 2 Asp and 
TM7Asn. 
Mutagenesis studies of the GnRH-R have identified glycosylation sites (Davidson et 
al., 1995), location of disulphide bridge between extracellular loop I and II (Davidson et al., 
1997; Cook et al., 1997 ), intermolecular transmembrane interactions (Zhou et al., 1994), 
and several putative ligand interacting sites which are Glu
301 (Flanagan et al., 1994), Lys121 ( 
Zhou et al., 1995), and Asn102 (Davidson et al., 1996). Since understanding the role of the 
GnRH-R in reproductive functions is crucial, knowledge of the structural conformation of 
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the GnRH-R interacting with GnRH may assist in the design of new GnRH analogues for 
therapeutic purposes. While there have been considerable evolutionary constraints on the 
structure and function of the mammalian GnRH-Rs, the far greater antiquity of the chicken 
GnRH-R provides an opportunity for unique amino acid substitutions to occur. There are 
different pharmacological properties between the mammalian and chicken GnRH-Rs. For 
example, the mammalian GnRH-R has a high affinity for [Arg8]-GnRH, whereas the 
chicken receptor has no selectivity for basic or neutral amino acids at this position (Millar 
et al., 1989). D-Trp6 incorporation does not enhance activity in the chicken receptor, but 
restored activity to analogues lacking Arg8 in the mammalian receptor. Moreover, some 
GnRH antagonists exhibit an agonist effect in the chicken pituitary gland, while they show 
full antagonism in the sheep (Jacobs et al., 1995). Therefore, the advantages of the present 
study will offer an approach tool, and useful information, to unravel the functional binding 
domain of the GnRH-R. It will also give an insight into the molecular basis of GnRH 
actions on the reproduction of chickens. 
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3.3 MATERIALS AND METHODS 
Materials 
The oligo-nucleotides used in the cloning of the GnRH-R cDNA are summarised in 
Table (3.1), and their positions on the chicken GnRH-R cDNA are illustrated in Fig. 3.1. 
Table 3.1 The nucleotide sequences of the primers, used in this 
study. N: A, C, G, and T; G(Aff): G or A or T. 





JH4s 5'-CTCGAA TTCAA(G)ATGACNGTNGCNTTT(C)GC-3' 
JH5s 5'-CTCGAATTAGNATT(A/C)TGGTAT(C)TGGTT-3' 
JH2a 5'-ACACTCGAGTGNACNGTA(T/G)ATG(A)TTCCACAT-3' 
JH5a 5'-ACACTCGAGAACCAATACCAA(T/G)A TNCC-3' 
JH6a 5'-CACTCGAGCCA(G)TAG(T/A)A TTNTG(A)NGGATC-3' 
~pecif,c primer 
YS1 5'-GCTGAGCACTTGTGCTGCCT-3' 
YS2 5'-CACTTGTGC TGCCTGACTTGCTG-3' 
YS3 5'-GGGCATCCTCTGGATCATGGC-3' 
YS4 5'-GGTGCATGTGTGCAGCAAACC-3' 





Fig. 3.1 The positions of the primers used in this study corresponding to the 
chicken GnRH-R cDNA. The degenerate primers (in purple) and the specific primers (in ---
green) are shown. "*" : stop codon; ORF: open reading frame; TM: transmembrane, "~ " : 















The sequence of GnRH analogues used in the study are shown in Table 3.2. All agonists 
were synthesised by conventional solid-phase methodology and were purified to more than 
95 % homogeneity, by preparative C-18 reversed-phase chromatography (Millar et al. , 
1989). Antagonist 26 was a gift from Dr. D. H. Coy (Tulane University, Medical Centre, 
New Orleans, LA, USA) and antagonists 27, 135-18, 135-25, 134-53, and 134-46 were 
from Prof. R. W. Roeske (Indiana University, Indianapolis, IN, USA). 
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_ Trp Tyr 
Arg Trp Tyr _ 
D-Ala N-Me-Leu Pro-NHEt 
Ac-D-Nal(2) D-a-Me-4-Cl-Phe D-Trp Ipr-Lys D-Tyr _ 
~c-D-Na1(2) D-4-Cl-Phe D-Pal(3) _ lpr-Lys D-Trp _ 
~c-D-Na1(2) D-4-Cl-Phe D-Pa1(3) _ 1-MePal D-Trp _ 
Ac-D-p-Cl-Phe D-4-Cl-Phe D-Trp _ _ D-Lys _ 
Ac-D-Na1(2) D-4-Cl-Phe D-Pal(3) _ 1-MePal D-Ipr-Lys _ 
Ac-D-Nal(2) D-4-CI-Phe D-Pal(3) _ Ile D-lpr-Ly _ 
D-Ala-NH2 
Ipr-Lys _ D-Ala -NH2 
Ipr-Lys _ D-Ala -NH2 
D-Ala-NH2 
lpr-Lys _ D-Ala -NH2 
Ipr-Lys _ D-Ala -NH2 
Amino acids (a.a.) in common with mGnRH are indicated by "_". Nal(2) : 3-(2-naphthyl)alanine; 4-Cl-
Phe: 3-( 4-chlorophenyl) alanine; a-Me-4-Cl-Phe: 2-methyl-3-(-chlorophenyl)alanine; Pal(3 ): 3-(3-
pyridyl)alanine; Nic-Lys: N"-nicotinoyllysine; Ipr-Lys: N" -isopropyllysine 
Methods 
3.3.1 Cloning the chicken GnRH-R gene 
Cloning a partial GnRH-R gene from chicken by PCR 
A series of degenerate primers designed against conserved amino acid residues of 
mammalian GnRH-R by Dr. Hapgood (Table 3.1 and Fig. 3.1), were tested to amplify up 
different regions of the chicken GnRH-R gene from chicken total genomic DNA by PCR. 
The primer combinations used. in PCR were JH1s/JH2a, JH2s/JH2a, JH4s/JH5a, and 
JH5s/JH6a. PCR was carried out in DNA thermal cycler (Perkin Elmer Cetus). The cycling 
63 
parameters of PCR were at 94 °C for 4 min, 35 amplification cycles (1 min at 93 °C, 2 min 
at 55 °C, and 3 min at 72 °C), 10 min at 72 °C, and 10 min at 4 °C. 
Screening a chicken genomic library 
7.5xI05 individual recombinants of a chicken genomic library, constructed in 
bacteriophage Lambda Charon 4A (Dodgson et al._, 1979), were screened in 20 (150 mm) 
petri plates. Duplicated nylon filters were lifted as described in the "TRH-R" section. The 
pCH 1 that is a partial gene of the chicken GnRH-R, encoding a region from the C-
terminal part of TM 6 to TM 7 of the chicken GnRH-R, was isolated by PCR with 
degenerate primers JH5s and JH6a (Fig. 3.2 and 3.3). The pCH I was used as a probe, and 
was labelled with a32P-dCTP by random hexamer priming ( Megaprimer labelling kit, 
Amersham). The filters were pre-hybridised for 3 hr at 42 °Cina solution containing 50% 
formamide, 2x PIPES, 1 % SDS and 100 µglml herring sperm DNA. After at least 3 h pre-
hybridisation, the labelled probe was added to the membranes and the hybridisation was 
carried out at 42 °C overnight. The filters were washed with lxSSC, 0.1 % SDS at room 
temperature for 15 min, in 0.5xSSC, 0.1% SDS at 50 °C for 20 min, and 0.2xSSC, 0.1% 
SOS at 50 °C for 20 min. 
5 'RACE (Rapid Amplification of the 5 'end) and nested PCR 
Four anti-sense primers to the chicken GnRH-R cDNA, YS3 to YS6, were designed 
from the nucleotide sequence data derived from the exon 3 of the receptor (pCH2) (Fig. 
3.2 and 3.3). The nucleotide sequences and positions of the primers were shown in Table 
3.1 and Fig. 3.1. 
cDNAs were synthesised by using the Marathon cDNA synthesis kit (ClonTech), 
from 2 µg total RNA of the castrated chicken pituitary ( a gift from Prof. Sharp). The YS6 
primer was used to initiate first strand synthesis. Marathon cDNA adaptors consisting of 
the sequence for the API and AP2 primers (Table 3.1), were ligated onto the ends of the 
cDNAs. The 5' -end of the chicken GnRH-R cDNA was amplified up by three rounds of 
nested PCR with KlenTaq polymerase (ClonTech), using the following combination of 
primers~ round 1 (API / YS5), round 2 (AP2 I YS4), and round 3 (AP2 / YS3). The 
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samples were subjected to the following condition: 94 °C for 2 min, 30 amplification 
cycles (30 sec at 94 °C, 30 sec at 66 °C, and 3 min at 68 °C), and 5 min at 4 °C. 
Amplification ofthe full-length chicken GnRH-R cDNA 
Two sense primers, YS 1 and YS2, were designed to the region 5' before the start 
codon of the chicken receptor (Table 3.1 and Fig. 3.1). Two rounds of nested PCR, with 
primer combinations (YS1/YS6 and YS2/YS5) were used to amplify up a full-length 
chicken GnRH-R cDNA from the castrated chicken pituitary cDNA. The cycling 
parameters of PCR were the same as described in 5'RACE. The PCR-products were sub-
cloned into the pMOS vector and sequenced. 
3.3.2 Characterisation of the chicken GnRH-R 
Cell culture and transfection : 
COS-1 cells were grown at 37°C in an humidified atmosphere containing 5% CO2. 
One or two days before transfection, the COS-1 cells were seeded by trypsin, and plated 
out in 12-multiwell dishes (Coming), coated with poly-D-lysine ( 10 µg/ml ), as mono-
layer cultures ( 0.6 - 1 x 105 cells/ 25mm well). The cells were transfected for 3.5 hr with 
the chicken GnRH-R subclones (pCH5, 6, or 7) ( 1- 0.5 µg/well ) or the human GnRH-R 
subclone ( 1- 0.5 µg/well ) (Chi et al. , 1993) which were all subcloned into the pcDNA 
vector, using a modified DEAE-dextran method (Cullen, 1987). For the inositol phosphate 
production assay, the cells were labelled with myo-[3H]-inositol (1 µCi/ml, Amersham) in 
M199 medium (supplemented 2% fetal calf serum and penicillin / streptomycin) for 16 - 22 
hr in a 37 °C incubator ( 10% CO2) 48 hr after transfection. The cells were also used for 
radio-ligand binding assay 48 hr after transfection. 
Inositol phosphate formation assay : 
IP formation was measured as previously described (Millar et al. , 1995). Briefly, 
the myo-[3H]-inositol labelled cells were washed twice with buffer A (140 mM NaCl, 
4mM KCl, lmM CaC}z and 1 mM MgC}z, 20mM HEPES, 0.1% BSA, and 8 mM D-
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glucose, pH 7.4) at 37 °C for 5 min, incubated with buffer A (containing 10 mM LiCl) in the 
absence and presence of different doses of GnRH agonists, or with antagonists in the 
presence of lnM or 10 nM cGnRH I (for cGnRH-R subclone), or of 1 nM mGnRH (for 
hGnRH-R subclone) at 37 °C for 1 hr. All experiments were performed in duplicate and 
repeated at least two times. 
Whole cell radio-ligand binding assay : 
The analogue [D-Ala6-N-a-MeLeu7, Pro9-NHEt]GnRH (GnRH-A) was iodinated as 
described (Millar et al, 1989). Binding of 1
25I-GnRH-A was measured in 12-well culture 
plates (triplicate) with transiently transfected COS-1 cells. Cells were washed for 5 - 10 min 
in ice-cold Buffer A, incubated for 3 hr at 4 °C in 0.5 ml of Buffer A containing 100,000 
cpm radio-ligand, alone, and with increasing concentrations of unlabelled GnRH agonists. 
Non-specific binding was determined in the presence of lµM unlabelled antagonist (A27). 
For the competition binding by GnRH antagonists, cells were incubated with various doses 
of antagonists at 3 7 °C for 3 hr, since antagonists are not internalised and have reduced "on" 
and "oft'' rate constants. After incubation, the cells were washed three times with ice-cold 
Buffer A (containing 0.5 % BSA). Cells were solubilised in 0.5 ml of 0.1 N NaOH and 
radioactivity counted. All experiments were repeated at least twice. 
Data Analysis: 
The values of Ki and EDso (IP formation) were calculated by non-linear regression 
analysis using the PRISM program (GraphPad Inc.). Dose-response curves ( each data point 
is a mean of all experiments) for IP formation and receptor binding assays were generated 
using the same program. 
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3.4 RESULTS 
Summary of the work in cloning chicken GnRH-R cDNA 
The chicken GnRH-R cDNA was cloned using a variety of strategies (Fig. 3.2), and 
the results of each strategy were illustrated in Fig. 3.3. As the receptor mRNA is expressed 
at extremely low levels, it could not be isolated by screening cDNA libraries ( constructed 
from the intact and castrated chicken pituitary glands). It has been suggested that the 
number of GnRH-Rs is up-regulated in the castrated chicken. However, no positive signals 
were detected after screening the castrated chicken cDNA library using a mouse GnRH-R 
cDNA probe, or chicken gene specific probe (a part of chicken GnRH-R gene). Therefore, 
this thesis will only address the strategies which were applied successfully, to isolate the 
GnRH-R cDNA. 
PCR was used to amplify a part of the chicken GnRH-R gene from the total 
genomic DNA, with degenerate primers IB5s and IB6a. The partial gene of the chicken 
GnRH-R was subcloned (termed pCHl) (Fig. 3.3) and was used as a probe to screen a 
chicken genomic library. This strategy succeeded in cloning the chicken receptor gene. 
After the Southern blot analysis of the receptor gene, the exon 3 of the receptor was 
obtained by sub-cloning (in the pSK- vector) and sequencing (called pCH2) (Fig. 3.2 and 
3.3). Additionally, the exon 2 of the receptor was identified by partial sequencing (pCH3) 
(Fig. 3.2 and 3.3). Four antisense primers were designed on the basis of the nucleotide 
sequence data of the exon 3 (pCH2) (Fig. 3.3). In order to get more 5'-end sequences of the 
receptor, 5' RACE was performed using a gene specific primer (YS6) to initiate first 
strands of the chicken pituitary cDNA and accompanied by three runs of nested PCR with 
primer combinations AP1/YS5, AP2/YS4, and AP2/YS3. The 5' un-translated region of the 
chicken receptor was identified by sequencing from pCH4 clone (Fig. 3.2 and 3.3). 
Therefore, two primers (YS1 and YS2) were designed according to the sequence data of 
the .5'-untranslated regions. Finally, full-length chicken GnRH-R cDNA clones were 
amplified by PCR with the two pairs of nested primers (YS 1/YS6 and YS2/YS5). 
However, the full-length cDNA clones contained various nucleotide sequence differences, 
which resulted in encoding different amino acid sequences from genomic sequences of the 
receptor. A "wild type" chicken GnRH-R was therefore constructed. The details of the 
results will be addressed in the following section. 
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Fig. 3.2 Summary of the work in cloning chicken GnRH-R cDNA. I 
1. Constructing cDNA 
library from the castrated 
chicken pituitary gland 
2. Screening the cDNA 
libraries using a a 32P -




No chicken GnRH-R 
cDNA clone was 
identified 
7. 5' RACE and nested 
PCR with a gene specific 
primer to initiate first strand 
cDNAs 
Results: 
Obtained the 5' un-
translated region (pCH4) 
Results: a. Cloning a partial 
chicken GnRB-R gene 
from total genomic DNA 
using a pair of degenerate 
primers (JH5s and JH6a) 
~ A partial chicken GnRH-R 
gene (pCHl ), encoding the 
C-terminus of TMt; to TM1, 
was identified 
As a probe 
As a probe 
5. Screening a chicken 
genomic library 
4. Re-screening the 
cDNA libraries 
No result!!! 
._ _______ ... ~ Results: 
Three chicken GnRH- R 
genomic clones were 
isolated 
Results: 
6. Southern blot analysis and 
Partial sequencing of a chicken 
GnRB-R genomic clone ~ Identified exon II (pCH3) 
and exon III (pCH2) of 
the chicken GnRH-R 
~ 8. Amplification of the 
full-length chicken 
GnRB-R cDNA using 
reverse transcriptase PCR 
... 
9. Constructing the "wild -
type" chicken GnRH-R cDNA 
(pCH7) according to the 
sequences of the genomic clone 
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Results: 
Identified two full-length 
chicken GnRH-R cDNA 
clones (pCHS and pCH6), 
which contain various 
mutated sequences 
Fig. 3.3 Diagram of cloned cGnRH-R cDNAs and genomic clones. The structure 
of the chicken GnRH-R gene is shown. Primers are indicated in purple 
colour (degenerate primers), and in green (specific primers). Amino acid 
sequences with positional number are shown in brown (wild-type), and in 
red (mutation). ORF: open reading frame; TM: transmembrane; *: stop codon. 
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Cloning of the chicken GnRH-R gene : 
As the chicken GnRH-R mRNA is of extremely low abundance, the conventional 
strategies for cloning, e.g. screening cDNA library, were unable to pick up positive signals 
at the cDNA level (data not shown). Therefore, PCR ~ known as the most sensitive 
technique, was applied to amplify a part of the chicken GnRH-R gene using degenerate 
primers, which were derived from the amino acid sequence data of cloned mammalian 
GnRH-Rs. In several sets of degenerate primers tested in PCR, the JH5s/JH6a combination 
was the only successful primer set to amplify a fragment of the chicken GnRH-R gene. 
The part of the chicken GnRH-R gene encoding the C-terminus of TM 6 to TM 7 
of the chicken GnRH-R, was amplified by PCR with JH5s and JH6a degenerate primers. 
The partial gene was cloned into the pMOS-Blue vector and verified by sequencing 
(designed pCHl) (Fig. 3.3 and 3.4). The deduced amino acid sequences of the pCHl 
exhibited 70 % and 50 % identity to those of frog and mouse counterparts, respectively. 
The pCHl became a useful tool for further cloning work. A chicken genomic DNA 
library was screened by hybridising with a 32P-labelled pCHl probe. Three positive 
clones of chicken GnRH-R gene were isolated from 7.5x10
5 recombinants in the first 
screening (Fig. 3.5). Of three positives, the chicken GnRH-R.genomic 22 clone was 
selected to carry out the secondary screening ( Fig. 3.6). 
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Fig. 3.4 Schema.tic representative of the pCHl, amplified by PCR 
with degenerate primers JH5s and JH6a, from the chicken 
total genomic DNA The deduced amino acid sequences 
were verified by sequencing, after being sub-cloned into 
the pMOS-Blue vector. 1M: transmembrane domain. 





Fig. 3.5 One of three positives (shown in duplicate), chicken 
GnRH-R. genomic 22, hybridised with a-32P-labelled 
pCHJ in 7.5xl fl plaques primary screening. The 
autoradiographs were exposed for 4 days and orientated 
by marking"."," .. ", and" ... " around the edge. 
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Fig. 3.6 Ample positives, hybridised with a-32 P-labelled pCHJ in 
the secondary screening (duplicate membranes) of the 
chicken GnRH-R.genomic 22. The autoradiographs were 
exposed for 5 hr and orientated by marking"."," .. ", and 
" ... " around the edge. 
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Five .single plaques of the chicken GnRH-R.genomic 22 clone were isolated from 
the secondary screening and were amplified. 10 µg DNA each of the chicken GnRH-
R.genomic 22 was digested with EcoR I and EcoR l/Pst I (Fig. 3.7, panel A), and the gel 
was subjected to Southern blot analysis by hybridising with a.-32P-labelled pCHl that 
contained 3'-untranslated region of the chicken GnRH-R (Fig. 3.7, panel B). A 2.7 Kb 
EcoRI/Pst I ( or 4.8 Kb EcoRI ) digest was hybridised with the pCHl probe, and sequenced 
after being subcloned into the pBluescript SK- vector (called pCH2) (Fig. 3.3). 
Fig. 3.7 Southern blot analysis of the chicken GnRH-R.genomic 22 clone by 
hybridising with a 31 P-labelled pCHJ. 
(A) Electrophoresis of 10 µg each DNA of the chicken GnRH-R.genomic 
22, digested with EcoR I or EcoR l/Pst I, on 1 % agarose gel with a 
ruler at the edge of the gel. 
(B) Autoradiograph of the Southern blot after overnight exposure to X-ray 
film. 4.8 and 2.7 Kb bands Gudged by the ruler) ofEcoR I and EcoR 
l/Pst I digested :fragments, respectively, were hybridised with the 
probe. 
A. 
1 2 ... 
--•. • .. --• ..... 
., . ..... 
3 
-








1 2 3 
The sequence data revealed that the pCH2 contained exon ill, which encodes the 
half intracellular loop ill to the C-tenninal tail of the chicken GnRH-R, and part of exon II 
(Fig. 3.3 and 3.8). Four antisense primers, YS6, YS5, YS4, and YS3, were designed 
according to the sequence data of the exon 3. These four primers were used in the next 
strategies, 5' RACE and nested PCR, to amplify the 5'-end region of the receptor (see the 
next section). 
Additionally, the EcoR I/Pst I digests of the chicken GnRH-R.genomic 22 were 
subcloned into the pSK- vector (digested with EcoR I/ Pst I) and partially sequenced. A 0.8 
kb EcoRI/Pst I digest (pCH3) contained a partial exon II (the fourth amino acid of N-
tenninus to half TM 4 of the chicken GnRH-R) (Fig. 3.3 and 3.9) Unfortunately, the pCH3 
contained most of the N-tenninal region but lacked an initiation codon (ATG), because the 
open reading frame was interrupted by an intron. 
74 
Fig. 3.8 The nucleotide and deduced amino acid sequences (in the antisense direction) 
of the pCH2 clone, subcloned into the pBluescript SK(-) vector digested with 
Pst L The nucleotide sequences ( capital black letters) and their deduced amino 
acid sequences (italic capital red letters) are displayed. Nucleotide sequences of 
the intron are in lowercase letters. TM: transmembrane domain [high-lighted 
by yellow colour, assigned according to those of the human receptor (Sealfon et 
al., 1997)]. Four primers, YS6 to YS3, are indicated. 
Anti-sense sequences : YS6 YS5 Stop codon 
5
' CTAGTCTCCTT TGGGTACATCTCTTC CACACCG GTTAACGGTTGTCCCATTGGA 
L R R K P V D R C V T N V T T G N S 
GCCACCTGATGTCACCTGGCCATTGACATCCCCATCCTTGGTGGTCTTCTCTGAGACTGA 
G G S T V Q G N V D G D K T T K E S V S 
GATGGGTTTGTGTCTCACATGCTGGCTAATGGCTGCTTCAATGCCCCTGAGACACAGTTG 
I P K H R V H Q S I A A E I G R L C L Q 
YS4 
CACGTCCTCCCGAAACG GGGGTGTACAGTCCATAAATGATGGGGT GGTGCATGTGTG 
V D E R F P T Y L G Y I I P 
CAGCAAACi AAAGAGAAAGAAGCTGTGGTTGATGTAdrCf GGCATCCTCTGGATCATGGC j 
r . _ P r E P s R N r vT E P M R Q I M A 
YS3 
TG ATGGAACCAGTACCACAGGCCTAGGAGGTAGTACGGGGTCCAGCAGATGATGAAGCT 
HFWYWLGLLY PTW IIrS 
GGCAACAATCACAATGGTCATCTTGAGAGTCTT ATGCGTGCCTTGGAGATGTGGTCATT 
A V V T M K L T K M R A K S I H D N 
ggagagag caaaaggacagcaggagg g 
aaggagaacgtaaccagcagtgggaatcccagaatgctgctgaaccataaggacctgct A 
CTTTTGTTGATCTTTAGCTGCT CTGATCTCCCAAATGATTCGGACGTAGCAAACAATCAT 
S K N I K L Q K S I E W I I R V Y C V I M 
GATGCTCAGGGGGGTGATATAGAGGGTGGTGAAGGTGAACATGTTGTAGACAGTTTCTT C 
I S ~ P T L T T F ~ I' M ~ Y ~ L ~ 
AGTGTGCTCGGAAGCTACCGTGAGTAACGCACTGTGTGAAGTTCCCTCCTGGGACCGTGTGC 
W H A R F S G H T V C Q T F N G G P V T ... / !f. 
ACGT GAAGAGAAATAGCTGGGGTGC 3 ' 
V I' F L Q P S 
stop 
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Fig. 3.9 Diagram of the pCH3, subcloned into the pBluescript SK(-) vector 
digested with Pst L The nucleotide sequences ( capital black letters) in 
the sense direction were identified by sequencing and their deduced 
amino acid sequences (italic capital red letters) are displayed below. 
Nucleotide sequences of the intron are in lower case letters. TM: 




5' ...................... . cttttcaaccttaa t aattctgtgatctctctctacgt a CAGCTGCTTTAATCG 
P A A L I E 
AAGCTGAACCGCCCCACCACCCCACCACGGAGGGGGACACCAACACCTCGGCCACTCACTGCCTG 
A E P P H H P T T E G D T N T S A T H C L 
GAGCACTGGGTCGAGCCCCGGTTCAC 




F CS/11 TAv G C 
A ..., 
CCCTTGGATGCGGCGTGGAATGTGACGGT CAGTGGTATGGTGGAGA CTTTCCTGCAAGCTCCTC 
P J ~ T V Q W Y G G D L 
TM TIT ---------
AACTTCCTCAAGCTCTTTGCCATGTATGCAGCAGCCCTGGTGTTGGTGGTTATCAGCCTGGACCGG 
F '\ AA '1 I V 
TMIV 
CATGCTGC GTCCTCCAGCCCTTCGCCCGTGC CGACGCCGCAATGGGCTGCTGCTGCGTGCTGCG 
1. AA VLQPFARA l 1 R \ L..,.., 1 
TGGCTGGGCAGTGTGCTGCTAGCATCACC3' 
L G S V 
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Cloning of the chicken GnRH-R cDNA : 
In order to get further 5' end sequences of the chicken GnRH-R, the cDNAs of 
castrated chicken pjtuitary glands were synthesised by using a Marathon cDNA synthesis 
kjt with a YS6 primer to initiate first-strand cDNAs. Then, the 5' end of the chicken 
receptor cDNA was amplified by using nested PCR with adapted primers and three gene 
specific antisense primers (i.e. AP1/YS5, AP2/YS4, and AP2/YS3 combinations). As the 
results show in Fig. 3.10, the PCR-product (panel A) was subjected to Southern blot 
analysis by means of hybridising with a-32P- labelled pCH3 (panel B). The 0.8, 0.9, and 
1.2 kb of PCR-products were hybridised a-32P- labelled pCH3. 
Interestingly, the positive bands 0.8, 0.9, and 1.2 kb were only produced in the 
PCR-products which were amplified from the first-run PCR products with primers AP2 & 
YS4 or AP2 & YS3 (Fig. 3.10), but not in that of the first-run PCR primed by nested 
primers AP1 & YS5. As the first-run PCR products were amplified from the cDNAs 
synthesised by a gene specific primer (YS6), the finding indicated that the chicken GnRH-
R mRNA is expressed at very low levels (see discussion section for the details). 
The positive bands were subcloned into the pMOS-Blue vector. One positive clone 
(pCH4) (Fig. 3.3) was isolated from 100 colonies by colony screening, probed with a-
32P-
labelled pCH3 (Fig. 3 .11 ), and its sequences were further confirmed by sequencing (Fig. 
3.12). Two sense primers, YS 1 and YS2, were designed according to the 5' end sequences 
of the pCH3 (Fig. 3.12). 
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Fig. 3.10 Analysis of the PCR-products amplified by nested PCRfrom the cDNAs of 
castrated chicken pituitary glands. 
(A) Electrophoresis of the PCR-products on 1 % agarose gel. Lane 1: ).. marker (Pst I); 
Lane 2: primed by adapted primer l(AP1) and YS5; Lane 3: AP2 and YS4; Lane 4: 
adapted primer 2 and YS3. 
(B) Southern blot analysis of the PCR-products hybridised with a.-3
2P-labelled exon II 
of the chicken GnRH-R gene, after 2 hr-exposure-to X-ray film. Positive bands of 
1.2, 0.9, and 0.8 Kb of the nested PCR-product, primed by AP2 and YS4or YS3, 
were indicated by the sizes. Interestingly, those bands were not detected in the 
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Fig. 3.11 Colony screening of the 0.8, 0.9, and 1.2 Kb 
bands of the nested PCR-products, subcloned 
into the pMOS-Blue vector. One positive 
colony ( in duplicate) was hybridised with a-
32P-labelled pCH3 (exon 2). 
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Fig. 3.12 Schematic representation of the pCH4, amplified by PCR with primers 
AP2 (adapted primer 2) & YS3 from the PCR-products of the AP2/YS4 
amplification and subcloned into the pMOS-Blue vector. Its partial 
nucleotide sequences of the 5' end and the 3' end (capital black letters) 
were identified by sequencing ( see top row) with deduced amino acid 
sequences (italic capital red letters). Two primers, YS 1 and YS2, were 
designed according to the sequences of the 5' end un-translated region. An 
initiate codon (ATG) is underlined. TM: transmembrane domain (high-
lighted in yellow); ...... : sequences not shown."*": stop codon. 
Sense direction : YS1 primer YS2 primer 
5 'IACTCACTATAGGGCTCGAGCGGC IACGCACGGAj GcTGAj cAcTTGTGCTGcqTGAT I 
AP2 primer T H G * 11 e 1, e 0 
r:;:;;::;:;;:rGGGACGGGCAGCATTACTCTTCGCTTCAGGGCATGTGCGTACCAGCTGCT 
~ D G Q H Y S S L Q G M C V P A A 
TTAATCGAAGCTGAACCGCCCCACCACCCCACCACGGAGGGGGACACCAACACCTCG 
L I E A E P P H H P T T E G D T N T S 
GCCACTCACTGCCTGGAGCACTGGGTCGAGCCCCGGTTCAC~GCAGCAAAGGTG 
A T H C L E H W V E P R F T E.__ 
CGTGTGGCCATCACAGCCGTCTTCTTCTTGCTGGCAGC ··-·-·--·-·-·------
A V I' l L 
·················································································· ······························{-·-.. ~TTGTGATTGTTGCC 
TMVI 
AGCTTCATCATCTGCTGGACCCCGTACTACCTCCTAGGCTTGTGGTACTGGTTCCAT 
w l :., ..., ~ v 
I ccAGCCATGATCCAGAGGATGccc I 3YS3 primer . . e d M r 9 B M e . 
( PMO~Blue vector ) 
The full-length chicken GnRH-R cDNA was amplified by nested PCR with primers 
YSl & YS6 and YS2 & YS5 for the first and the second run PCR, respectively. The PCR-
products were subcloned into the pMOS-Blue vector. Two clones, pCH5 and pCH6, were 
isolated. It was confirmed by sequencing that they contained an entire open reading frame 
of the chicken GnRH-R (Fig. 3.3 and 3.13). A comparison of the nucleotide sequence of 
these clones relative to the those of the genomic clones, identified a number of differences 
that might have arisen during the PCR reaction or represent polymorphism. The pCH5 
contained an amino acid substitution of Arg189 compared to Cys189 of the genomic clone. 
The CH6 showed nucleotide substitutions resulting in amino acid substitutions of Gln40 for 
Lys40, and Tyr75 for His75 compared with the genomic sequences. Both clones showed a 
substitution of Arg338 for Gln338 (Fig. 3.13). As it is uncertain whether these differences 
represent polymorphism or PCR errors, three different cDNA fragments from pCH5, 
pCH6, and pCH2, were ligated together to reconstruct a cDNA encoding identical amino 
acid sequences to those of the genomic clone (Fig. 3 .14 ). The Xba 1/Sph I fragment from 
the pCH5 was ligated to the Sph 1/EcoR I fragment of the pCH6, eliminating the amino 
acid substitutions at positions 40, 75, and 189. In order to eliminate the substitution at 
position 338, the Not I/Ava I fragment from this chimerical clone was ligated to the Ava 
1/Pst I fragment from pCH2, and subcloned into the pSK vector ( called cGnRH-R. W or 
pCH7) (Fig. 3.3). 
The Not I/Xho I fragment of the cGnRH-R.W was sub-cloned into the mammalian 
expression vector pcDNA I/AMP ( Invitrogen), digested with Not I/Xho I. This chicken 
GnRH-R/pcDNA amp subclone ( cGnRH-R subclone) was sequenced in both directions 
using automated sequencing (Bio-Rad), and it was verified that encoded amino acid 
sequences are identical to those of the genomic clone. 
The deduced amino acid sequences from the cGnRH-R. W clone are shown in Fig. 
3.15, including those of the human and catfish GnRH-Rs. The details of comparative 
amino acid sequences will focus on different features of the chicken GnRH-R from the 
human ( or mammalian) homologue, rather than from the catfish receptor, because there 
are distinct pharmacological properties between both receptors (see "receptor binding" and 
"inositol phosphate formation" sections). 
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Fig. 3.13 Schematic diagram of two full-length chicken GnRH-R 
cDNA clones, pCHS and pCH6, subcloned into the pMOS-
Blue vector. The various deduced amino acids are shown in 
italic capital letters with a positional number, and shown in 
pink colour where they differ from genomic sequences, with 





Fig. 3.14 Schematic diagram of constructing a wild-type cGnRH receptor cDNA. 
A chimerical clone was created by ligating two fragments, the Xba 1/Sph I fragment 
of the pCH5 and the Sph I/EcoR I fragment of the pCH6, together. The wild-type 
cGnRH-R clone (cGnRH-R.W) was constructed by subcloning the Not I/Ava I 
fragment of the pCH5&pCH6 and the Ava 1/Pst I fragment of the pCH2 into the Not 
1/Pst I digested pSK- vector. ORF: open reading frame; TM: transmembrane domain; I: intron; the 
mutated sequences (pink); the wild-type sequences (black). PMOS-Blue: a vector; "?" : un-identified region. 
Aval 
pCH5 &pCH6 
subclone into the 
pBluescript SK-vector (digested 




subclone into the 
pBluescript SK- vector 
(digested with Not 1/Pst I) 
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Comparison of structural features between the chicken and mammalian GnRH-Rs 
There is a strikingly different appearance of the chicken GnRH-R from the 
mammalian homologues, in that it contains the C-terminal tail that is also present in the 
catfish GnRH-R {Tensen et al., 1997) (Fig. 3.15). Compared with the amino acid sequences 
of the human receptor, the chicken receptor only shares 39 % identity, excluding the C-
terminal tail (Fig. 3.15). The N-terminus and intracellular loops (IL) are more divergent, 
while having a comparatively higher level of amino acid sequence identity within the 
transmembrane domains {TM) (more than 40 %, except the TMi, only 33 %) and the 
extracellular loops (EL). Moreover, based on a survey of conserved residues in a large 
number of G-protein-coupled receptor sequences, an arrangement of the transmembrane 
helices has been proposed in which TM 7 is believed to lie adjacent to TM 2, and TM 6 is 
adjacent to TM 3. In the amino acid sequence comparison, it appears that the percentage of 
amino acid identity between TM 2 and TM 7 as well as between TM 3 and TM 6 are similar 
(46 % vs. 52 %, and 65 % vs. 66 %, respectively). Intriguingly, the chicken GnRH-R 
consists of a longer N-terminus (7 amino acids longer), an intracellular C-terminal tail, and a 
short IL 1 (comprising only 6 amino acids) (Fig. 3.15). 
The chicken GnRH-R contains three potential sites for N-linked glycosylation (Ans-
X-Ser/Thr)(Fig. 3.15). Besides two located in the N-terminus and the C-terminus of TM 2, 
which are the same as the mammalian counterparts, another was found within EL 2. 
Furthermore, most GPCRs contain a number of conserved cysteins (Cys), some of which 
appear to play a role in maintaining the active conformation of the receptor. There are five 
Cys conserved in the chicken and human receptors, which are located at TM 3, EL 2, TM 5, 
TM 6, and TM 7, but an additional highly conserved Cys among GPCRs was found in the C-
terminal tail of the chicken receptor. Interestingly, two highly conserved GPCR residues are 
Asp in TM 2 and Asn in TM 7, while it appears to be interchanged at these loci in 
mammalian GnRH-Rs ( i.e. TM 2 Asn and TM 7 Asp). Surprisingly, they are TM2 Asp and 
TM 7 Asp in the chicken, also in the catfish receptor and other non-mammalian vertebrates 
(frog and goldfish, unpublished data). The 'DRY' (Asp-Arg-Tyr) motif in the end of TM 3 is 
conserved among the GPCRs and appears to play a role in the coupling of the receptors to G-
proteins. While a Ser replaces the Tyr residue in the 'DRY' motif in mammalian GnRH-Rs, 
a His instead of Tyr in the chicken and in the catfish receptor and other non-mammalian 
vertebrates (unpublished data). More details of the comparative structure will be addressed 
in the discussion section. 
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A) 
atg tgc gta cca get get tta ate gaa get gaa ccg CCC cac cac CCC ace 
M C V p A A L I I!: A g- p p B B p T 
acg gag ggg gac ace aac ace tcg gee act cac tgc ctg gag cac tgg gtc 
'l' E G D 'l' N 'l' s A 'l' B C L E B w V 
gag CCC egg ttc aca,. aaa gca gca aag gtg cgt gtg gee ate aca gee gte 
E p R I' 'l' K A A It V R V A I 'l' A V 
ttc ttc ttg ctg gca gcg tgc age aat aca gca gtg ctg ggc age ctg ctg 
I' p L L A A C s N 'l' A V L G s L L 
agg aag agg agg aag tgc cac gtg egg cca ctg ate etc age ctg gcg ctg 
R lt R R lt C R V R p L I L s L A L 
get gac ctg ctg gtg aca gtg gca gtg atg CCC ttg gat gcg gcg tgg aat 
A D L L V 'l' V A V M p L D A A w N 
gtg acg gtg cag tgg tat ggt gga gac ctt tee tgc aag etc etc aac ttc 
V T V Q w y G G 0 L s C It L L N F 
etc aag etc ttt gee atg tat gca gca gee ctg gtg ctg gtg gtt ate age 
L lt L F A M y A A A L V L V V I s 
ctg gac egg cat get gee gtc etc cag CCC ttc gee cgt gee cga cgc cgc 
L D R B A A V L Q p F A R A R R R 
aat ggg ctg ctg ctg cgt get gca tgg ctg ggc agt gtg ctg eta gca tea 
N G L L L R A A w L G s V L L A s 
CCC cag eta ttt etc ttc cac gtg cac acg gtc cca- gga g.gg aac ttc aca 
p Q L F L I' B V B T V p G G N F 'l' 
cag tgc gtt act cac ggt age ttc cga gca cac tgg gaa gaa act gtc tac 
Q C V T B G s F R A R w E E T V y 
aac atg ttc ace ttc ace ace etc tat ate ace CCC ctg age ate atg att 
N M F T F T 'l' L y I 'l' p L s I M I 
gtt tgc tac gtc cga ate att tgg gag ate agt aag cag eta aag ate aac 
V C y V R I I w E I s lt Q L lt I N 
aaa agt ctg gta aga agt caa aat gac cac ate tee aag gca cgc atg aag 
K s L V R s Q N D B I s K A R M lt 
act etc aag atg ace att gtg att gtt gee age ttc ate ate tgc tgg ace 
'l' L It M 'l' I V I V A s F I I C w T 
ccg tac tac etc eta ggc ttg tgg tac tgg ttc cat cca gee atg ate cag 
p y y L L G L w y w F B p A M I Q 
agg atg CCC gag tac ate aac cac age ttc ttt etc ttt ggt ttg ctg cac 
R M p E y I N B s F F L F G L L B 
aca tgc ace gac CCC ate att tat gga ctg tac ace CCC tcg ttt egg gag 
'l' C 'l' 0 p I I y G L y T p s F R B 
gac gtg caa ctg tgt etc agg ggc att gaa gca gee att age cag cat gtg 
D V Q L C L R G I E A A I s Q R V 
aga cac aaa CCC ate tea gtc tea gag aag ace ace aag gat ggg gat gtc 
R B lt p I s V s E K 'l' 'l' lt D G 0 V 
aat ggc cag gtg aca tea ggt ggc tee aat ggg aca ace gtt aac acg gtg 
N G Q V T s G G s N G 'l' T V N '1' V 
tgc tga 
C * 
... -· -· --··· ·- - - -- -·--· --···-- ·---·· --··· ....... ----.- - --- - - - - -- - • --- -~,-.-- - ·,,,, .•• ·-::rt .--~ ···"7- .-., -cn,:,;....,,..-n,-..-,1-r,...,,.-·y~, 
Fig. 3.15 A) The nucleotide and amino acid sequences of the chicken GnRH-R 
B) Alignment of the deduced amino acid sequences with the chicken, 
catfish, and human GnRH receptors. The transmembrane domains 
(TM)(yellow shaded regions) are assigned according to those of the 
human receptor (Sealfon et al., 1997). Identical sequences amongst 
three species are shown in red letters, and conservative changes are 
shown in blue letters. IL: intra-cellular loop, EL: extra-cellular loop, 
" .... ": pace, "*": stop codon, and the numbers: positions of amino acids 
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WYGGD LS :rL LNl'LKL- r AAALVLVVI S 
WYAGD ANC~L l«:FLKLF B SAArIL TVVS 
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I 
1r°rM IV20 
P FAR .. AR RRH ~ WLQ SVLLASPQLF LFHVHTVPGG 
LDTLDAG RRH RRNLLTAWI L SLLLASPQLF I FRAiltAICGV 




N ..... FTQC VTHGSFRAHW E BTVY TF IVCYVR. IW 
D ..... FVQC ATHGSFQQHW Q BTAYNMFBF MSLC'!TRI LV 
SGQTICVFSQC VTHCSFSQWW H QU'YNF FTF SCLrIIPLFI ~ LI CNJUCI I F 
I 
200 240 
I IL Ill 11 KQL ..• K I ... NICSLVR SQNDHI SICAR M 
RQMHRSIC DICAGEPCLRR SGTDMI PICAR M ,T· I' '1T I II VAS FVI 'W'~n 




EL Ill TMVII I 
Y LLGLWYWF B PAMI QRMPE TI S 'FLFQ LLBTCTDPII SFRE 
YL ,GLWYWF Q PQMLHVIPD rvB FFVFQ HUffCC "VI SFRA 
YVLG,W WF D PEMLNRLSD PVHHFFFLFA r LHPc r DPLL .Grrs * 
320 360 
I 
DVQL .. CLRG IEA.AISQ.H VRHICPISVSE ICTTICDGDVNG QVTSGGSNGT 
DLSRCFCWRN QNASAICSLPH FSGHRREVSG EAESDLGSGD Q.PSGQ* 
TVNTVC* 
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Whole cell radio-ligand binding assay 
Agonist study: 
The binding affinities of agonists were determined by competing 1251-GnRH-A (Ki: 
3.0 ± 0.3 nM and 1.5 ± 0.4 nM for the chicken and human receptors, respectively) with 
increasing doses of cold agonists in the COS-I cells expressing the chicken receptor cDNA 
subclones or the human receptor subclone. The cGnRH I exhibited no significant difference 
in binding affinity for chicken GnRH receptor subclones (pCH5 and pCH6) and for the 
cGnRH-R.W subclone (data not shown), indicating that the pCH5 and pCH6 are functional 
transcripts; even though, they possess several amino acid sequences differing from genomic 
sequences of the chicken receptor. 
The cGnRH-R. W were further characterised by employing several GnRH agonists to 
measure their binding affinities for the receptor. The dose response curves of the competition 
binding for the chicken and human GnRH receptors by agonists are shown in Fig. 3.I6 and 
the affinities in Table 3.3. 
In the chicken receptor (Fig. 3.I6, panel A; Table 3.3), the binding affinities of 
cGnRH II and [D-Arg6]cGnRH II presented 11-fold and I5-fold, respectively, higher than 
that of cGnRH I. There was no significant difference between cGnRH I and mGnRH, nor 
between cGnRH II and [D-Arg6] cGnRH II. On the other hand, the human receptor (Fig. 
3.16, panel B; Table 3.3) presented a different ligand-selectivity. The mGnRH (Ki: 4.8 nM) 
had a 3-fold and 10-fold higher affinity than cGnRH II and [D-Arg6]cGnRH II, respectively, 
for the human receptor. The affinity of cGnRH I exhibited 40-fold less than that of mGnRH 
for the human receptor. 
Antagonist study: 
The binding affinity of antagonists was measured by means of competing 1251-GnRH-
A with increasing doses of cold antagonists on the COS-I cells expressing the chicken and 
human GnRH receptors. The reason that the 1251-GnRH-Agonist was used to measure 
antagonist binding instead of 1251-GnRH-Antagonist, is due to low affinities of the selected 
antagonists for the chicken receptor. The affinity of the antagonists for the chicken receptor 
was similar to the background level ( data not shown). 
In general, the affinity of six selected antagonists for the chicken receptor presented 
10-fold less than those for the human receptor in each individual antagonist (Fig. 3.I 7, Table 
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3.3). In the chicken receptor (Fig. 3.17; panel A; Table 3.3), the antagonist 27 was found to 
be the most potent peptide amongst the selected antagonists. Antagonists 134-46 and 134-53 
showed an un-distinguishable affinity for the chicken receptor. In addition, antagonists 135-
18 and 135-25 showed very low affmity for the chicken receptor. Interestingly, the 
antagonists 135-18 and 135-25 are full and partial agonist for the chicken receptor, 
respectively ( see IP assay described below ). 
In the human receptor (Fig. 3.17; panel B; Table 3.3), the antagonists (with the 
exception of antagonists 135-25 and 135-18) showed a similar affinity for the human 
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Fig. 3.16 Displacement o/125I-[D-A/a6, N-Me-Leu7, Pro9NHEt}GnRH 
(
251-GnRH-A) by GnRH agonists in COS-1 cells expressing. the 
chicken (A) and human (BJ GnRH receptors. Binding of 12 1-
GnRH-A in the presence of various concentrations of chicken 
GnRH I (CI), chicken GnRH II (C II), mammalian GnRH 
(mGnRH), [D-Arg6] cGnRH II ([D-Arg6] CIT), and GnRH-A 
([D-Ala]) was measured by whole-cell binding assay. Data 
represents the mean± S.E. of two to three experiments performed 
in triplicate. (The binding of cGnRH I on the hGnRH-R was 
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Fig. 3.17 Displacement of 115 I-/D-Ala6, N-Me-Leu 7, Pro9NHEt}GnRH 
{115/-GnRH-A) by GnRH antagonists on COS-I cells 
expressing the chicken (A) and human (B) GnRH receptors. 
Binding of 1251-GnRH-A in the presence of various 
concentrations of antagonists 27 (A 27), 26 (A 26), 134-53 
'(A53), 134-46 (A46), 135-25 (A25), and 135-18 (Al8) was 
measured by whole-cell binding assay. The experiment was 
performed once, in triplicate. 
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Inositol phosphate formation assay 
Three subclones, cGnRH-R.W (pCH7), pCH5 and pCH6, were functional 
constructs confirmed by TP production assay (data not shown). The pharmacological 
properties of the cGnRH-R.W subclone (cGnRH-R cDNA) were further characterised by 
applying different GnRH agonists and antagonists to measure their activities on stimulating 
IP formation after being expressed in COS- I cells. 
Agonist study: 
In the chicken receptor (Table 3.3; Fig. 3.18, panel A ), cGnRH II and [D-
Arg6]cGnRH TT generated profound differences in TP formation from those of cGnRH I 
and mGnRH , as compared with the results of receptor binding. [D-Arg6] cGnRH II was 
the most potent peptide in IP formation: 2-, 42-, and 126-fold higher than cGnRH II, 
mGnRH, and cGnRH I, respectively. cGnRH II was the second most potent peptide: 20-
and 63-fold higher than mGnRH and cGnRH I, respectively. However, cGnRH I and 
mGnRH both exhibited similar potency in this experiment. On the other hand, in the 
human receptor (Table 3.3; Fig. 3.18, panel B), mGnRH was the most potent peptide in 
stimulating IP production, followed by [D-Arg6]cGnRH II and cGnRH II. cGnRH I was the 
least potent peptide to stimulate IP production in the human receptor. 
Antagonist study: 
The antagonist study was performed by measuring IP production at various doses of 
antagonists in the presence or absence of cGnRH I ( 1 nM or 10 nM) and mGnRH ( 1 nM), 
respectively, in COS-I cells expressing the chicken and human receptors. Antagonists 
134-53, 134-46, and 27 presented full antagonisms in both chicken and human receptors 
(Fig. 3.19). Antagonists 134-46 and 134-53 showed a 15-fold more potent effect in human 
than in chicken, while antagonist 27 exhibited 30-fold more potency in human (Table 3.3). 
Intriguingly, antagonists 135-18, 135-25, and 26, which have D-Lysine in position 6, 
exerted agonist effects in the chicken receptor (Fig. 3.20, left panel). The maximal 
stimulation mediated by antagonist 135-18 was equivalent to one obtained by cGnRH I, 
despite the agonisim being only 8 % as potent as cGnRH I (Table 3.3). Nevertheless, this 
antagonist did not show any antagonism in the chicken receptor, while assessed by IP 
production in the presence of 1 nM cGnRH I (Fig. 3.20, left panel). The results suggested 
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that antagonist 135-18 is a full agonist in chicken receptor. Antagonists 135-25 and 26 
acted as partial agonists in the chicken receptor, by exhibiting 40 % and 15 % of maximal 
stimulation by cGnRH I, respectively (Fig. 3.20, left panel). In contrast, the three 
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Fig. 3.18 Dose-response curves/or inositol phosphate production 
stimulated by GnRH agonists in COS-1 cells expressing the 
chicken (A) and human (B) GnRH receptors. Peptides are 
chicken GnRH I (Cl), chicken GnRH II (CII), mammalian 
GnRH (mGnRH), and [D-Arg6] chicken GnRH II ([D-Arg6] 
CII). Data is shown as mean± S.E .. Each curve is representative 
of three to four experiments performed in duplicate. 
94 
(A) 








Basal -10 -9 -6 
-10 -9 -6 
Basal -9 -6 
• A 134-53 alone 
a A134¢3-+Cl (1nM) 
-7 -6 -5 
• A 134-46 alone 
a A 134-46 -+Cl (1 nM) 
-7 -6 -5 
• "'27 alone 
a "'27+0 (1nM) 
-7 -5 
hGnRH-R subclone 
-Basal -11 -10 -9 
-Basal -10 -9 
• A 134¢3 alone 
o A 134-53+mGrRl-t;-9E) 
-8 -7 -6 -5 
• A 134-46 alone 
o A 134-46-+mGrRi11 nM) 
-8 -7 -6 -5 
• "'27 alone 
O "'27~(1nM) 
- ---- - --- --+= ~ 
Basal -10 -9 -6 -7 -6 
GnRH Analogues Log [M] 
Fig. 3.19 Effects of antagonists on inositol phosphate production in the COS-1 cells 
expressing the chicken and human GnRH receptors. IP production was 
measured in the presence of various concentrations of antagonists, i.e., (A) 
A134-53 , (B) Al34-46, and (C) A27, with 1 nM of cGnRH I or without, 
and with 1 nM mGnRH or without in COS- I cells transfected with chicken 
and human GnRH-R cDNAs, respectively. Data are the means of three or 
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Fig. 3.20 Effects of antagonists on inositol phosphate production in the COS-1 
cells expressing the chicken and human GnRH receptors. 
IP production was performed in the presence of various concentrations 
of antagonist (A) Al35-18, (B) Al35-25, and (C) A26, as described in 
the legend to Fig. 3.19. (The Al35-25 experiment was performed in the 
presence of 10 nM cGnRH I or without.) 
96 
3.5 DISCUSSION 
Conserved structural features between the chicken GnRH-R and GPCRs 
The deduced amino acid sequences of the chicken GnRH receptor cDNA revealed 
that the chicken receptor comprises several highly conserved residues amongst GPCRs. All 
the GPCRs contain consensus sequence (Asn-X-Ser/fhr) for N-linked glycosylation, which 
may be involved in the expression and stabilisation of membrane receptors (see review 
Strader et al., 1994). There are two identified N-glycosylation sites within the N-terminus 
of the mouse GnRH receptor (Asn4 and Asn18) and one in the human receptor (Asn18), 
which has been shown to play a role in receptor expression or stability, but not involved in 
ligand binding interactions (Davidson et al., 1995; Davidson et al., 1996). The chicken 
receptor contains two potential N-glycosylation sites in the N-terminus (Asn23) and EL 2 
(Asn185). Interestingly, the catfish receptor consists of four potential glycosylation sites in 
the N-terminus (Tensen et al., 1997). 
Furthermore, the chicken receptor possesses highly conserved Cys residues in the 
junction of EL 1-TM 3 (Cys 114 ) and in EL 2 (Cys 189 ), which are also conserved in the 
catfish receptor (Tensen et al., 1997). The homologous two Cys residues are involved in 
forming a disulphide bridge that constrains a functional structure of the receptor in GPCRs 
(Dixon et al., 1987a; Dohlman et al., 1990; Perlman et al., 1995), and specifically in the 
human (Davidson et al., 1997) and the mouse GnRH receptors (Cook et al., 1997). There is 
an additional highly conserved Cys residue in many GPCRs. This residue has been shown 
to be palmitylated and the palmityl group may anchor the C-terminus in the plasma 
membrane and form a loop structure, which is proposed to be important for interactions 
with G proteins (Ovchinnikov et al., 1988; O'Dowd et al., 1989). Interestingly, an 
homologous Cys residue in the mouse TRH receptor (Cys335 ) appears to play a role in 
restraining the receptor in an inactive conformation and in rapid internalisation of the 
receptor (Nussenzveig et al., 1993a). This Cys residue (Cys328) is also conserved in the C-
terminal tail of the chicken receptor, which is absent from the mammalian GnRH receptors, 
but is present in the catfish receptor (Tensen et al., 1997) and other vertebrate's receptors 
(Frog and Goldfish, unpublished data). 
The highly conserved Pro residues located within the TM 4 - TM 7 of most GPCRs 
are suggested to take a part in changing the regular structure of receptors and may be 
important in the formation of the binding pocket (see review Probst et al., 1992). The 
97 
chicken GnRH-R contains these Pro residues, Pro171 (TM 4), Pro216 (TM 5), Pro273 (TM 6), 
and Pro311 (TM 7), which are also conserved in the mammalian and catfish receptors. 
Conserved structural features between the chicken and mammalian GnRH-Rs 
Despite the fact that the amino acid sequences of the chicken GnRH-R only share 
about 40 % identity to those of the mammalian counterparts, several important structural 
features are conserved between the chicken and mammalian GnRH-Rs over millions of 
years of evolution. These include the putative binding sites of the receptor and the residues 
for G-protein coupling. 
Through mutagenesis studies, the residues of the mammalian GnRH-Rs, which are 
involved in ligand-interactions, were identified. Lys 121 in TM 3 of the human receptor is 
important for interacting with GnRH agonist homologues, but is not involved in antagonist 
binding (Zhou et al., 1995). The finding also suggested that the Lys residue may interact 
with the electron-dense aromatic rings of His2 or Trp3 of the ligand. Asn 102 located in the 
C-terminus of TM 2 plays a role in high affinity binding of agonists and is proposed to 
dock the glycinamide C terminus of the ligand (Davidson et al., 1996). Glu301 residue 
within EL 3 of the mouse receptor was established to be forming an electrostatic interaction 
with the Arg8 residue of mGnRH (Flanagan et al., 1994). These three residues are 
completely conserved in the chicken receptor, also in the catfish (T ensen et al., 1997), frog, 
and goldfish receptors (unpublished data). 
The conserved DRY/SXXV/IXXPL/1/F motif, which is located at the C-terminus of 
TM 3 to the N-terminus of IL 2, plays a pivotal role in G protein coupling. The mammalian 
GnRH-Rs contain a Asp-Arg-Ser (DRS) motif which is instead of the Asp-Arg-Tyr (DRY) 
motif amongst GPCRs. The Arg residue in the DRS motif has been shown to have a major 
effect on signal transduction and internalisation in the mouse GnRH-R, while the Ser 
residue exhibits no effect on both aspects (Arora et al., 1997). The motif is present "Asp-
Arg-His" (DRH) in the chicken, catfish (Tensen et al., 1997), frog and goldfish receptors 
(unpublished data). The motif XXV/IXXPL/1/F, followed on from the DRS motif, is 
critical for interacting with G-protein and mediates signal transduction in other GPCRs 
(Probst et al., 1992; Savarese and Fraser, 1992), especially in the mammalian GnRH-R 
(Arora et al., 1995). The chicken GnRH-R contains the XXVXXPF motif on homologous 
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loci, and the XXIXXPL motif presents in the catfish (Tensen et al., 1997), frog, and 
goldfish receptor (unpublished data). 
The C-terminal part of the receptor IL 3 has been established to play a role in G-
protein coupling in a 1-adrenergic receptor (Cotecchia et al. , 1990), ~2-adrenergic receptor 
(Samama et al., 1993), and TRH-R (Nussenzveig et al. , 1993b). The Ala261 residue of the 
human GnRH-R was identified to be important for G-protein coupling (unpublished data). 
In this study, the Ala261 residue mutated to Lys, Glu, Phe, Leu, and Ile results in complete 
uncoupling. In contrast, mutations of the Ala residue, which locates in an homologous 
loci in a 1-adrenergic receptor (Kjelsberg et al., 1992), leads to a constitutive activity. 
Interestingly, the chicken GnRH-R conserved the Ala residue (Ala252 ), so does the catfish 
(Tensen et al. , 1997), frog, and goldfish (unpublished). 
Different structural features between the chicken and mammalian GnRH-Rs 
The general structural features of the chicken GnRH-R revealed that the chicken 
receptor comprises several unique features in comparison with the mammalian receptors: a 
longer N-terminus, a short IL 1, lack of a additional Cys residue in the junction of EL 1 
- TM 3, and a C-terminal tail. 
There are additional two Cys residues in the junction of EL 1- TM 3 ( except 
porcine) and TM 5 of the mammalian receptors, but absent in chicken and catfish. It has 
been demonstrated that the additional Cys residues in the junction of EL 1- TM 3 forms a 
disulphide bond with a Cys within the N-terminus in the human (Davidson et al., 1997) and 
mouse GnRH-R (Cook et al. , 1997). On the other hand, the chicken receptor possesses 
several Cys residues in the N-terminus and TM 1 (i.e. Cys2 ,Cys29, and Cys58), which are 
absent in the mammalian receptor. 
Two residues, an aspartic acid (Asp) in TM 2 and an asparagine (Asn) in TM 7, are 
conserved in over 95 % of GPCRs. The TM 2-Asp is important for agonist binding and G-
protein coupling in many GPCRs (see review Probst et al., 1992). Intriguingly, the 
mammalian GnRH-Rs appears to be interchanged at both loci (i.e. TM 2-Asn and TM 7-
Asp ). It was proposed that the residues in the mammalian receptor play an important role jn 
maintaining the structural conformation of the receptor which is essential for interacting 
with other loci on the receptor to trigger the signalling cascade (Zhou et al. , 1994). The 
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chicken receptor consists of two Asp residues in these loci (i.e. Asp87Asp310), as does the 
catfish receptor. 
Another feature of the chicken receptor is containing a C-terminal tail, which is 
absent in the cloned mammalian receptors, but is present in the catfish receptor (Tensen et 
al., 1997). One highly conserved Cys residue present in most GPCRs, which is established 
' 
to be palmitoylated, is also conserved in the chicken GnRH-R (as described above). In 
addition, it is well documented that the C-terminus plays a vital role in receptor's 
desensitisation and internalisation to regulate the receptor-G protein signalling in other 
GPCRs (Benovic et al., 1988; Blumer and Thomer, 1991). In the regulation by 
heterologous desensitisation, receptors phosphorylated by protein kinases A and/or C have 
a reduced ability to activate G protein. Consensus sites of phosphorylation for protein 
kinase C [(RIK.1.3, X2.o)-S!f-(X2.o, RIK.1.3) or S!f-(X2.o, RIK.1.3) or (RIK.1.3, X2.o)-S!f] 
(Kennelly et al., 1991) were located in the C-terminal tail of the chicken receptor, as well 
as in the C-terminal portion of IL 3, which has been shown to be important for G-protein 
coupling in the a 1-adrenergic receptor (Cotecchia et al., 1990). Those consensus sites were 
also found in the catfish receptor. However, the mammalian receptors lack the C-terminal 
tail. Highly correlatively, the mammalian receptor does not undergo rapid desensitisation 
(Anderson et al., 1995; McArdle et al., 1995). 
There are five potential phosphorylation sites that were located in IL 1, the N-
terminal part of TM 2 and IL 2 of the mammalian receptor, whereas they are absolutely 
absent in the chicken homologue. Coincidentally, two potential sites in IL 2 are proximal to 
the DRSxxV/lxxPL motif, which is involved in G protein coupling and agonist-induced 
receptor internalisation (Arora et al., 1995). No potential phosphorylation site in IL 2 was 
identified in non-mammalian vertebrates' receptors (the chicken and catfish receptors). It is 
of interest to notice that another three potential sites were located at between IL 1 and N-
terminal portion of TM 2 in mammals, where the receptors have a "TM 2-Asn / TM 7-Asp" 
structural combination. Taken together, it is suggested that distinct regions for regulating G 
protein coupling might be present in non-mammalian and mammalian species. 
Extraordinarily interesting, the amino acid sequences of the chicken GnRH-R 
shares about 40 % identity to the mammalian homologues, whereas it exhibits 
approximately over 60% identity amongst non-mammalian receptors (including chicken, 
frog, catfish, and goldfish). However, the chicken TRH-R shows over 80 % identity to the 
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mammalian counterparts (see the chicken TRH-R section). The drastic difference in 
structural features between the non-mammalian and mammalian GnRH-R is acquired by an 
evolutional selection over millions of years. It suggests the unique structural features of the 
mammalian GnRH-Rs might be required for a functional demand. Also, it is of interest to 
note that different receptors in the same tissue, e.g. GnRH-R and TRH-R, might have been 
constrained in a different way through millions of years of evolution. This is a phenomenon 
beyond the scope of this thesis to interpret here. 
Differential agonist-selectivity between the chicken and mammalian GnRH-Rs 
The pharmacological properties of the cGnRH-R were initially characterised using 
a selection of naturally-occurring GnRH analogues to measure their activities on receptor 
binding and stimulating IP production. The results revealed that cGnRH I and mGnRH had 
a similar binding affinity for the chicken receptor and were equipotent in stimulating IP 
formation, suggesting that the chicken receptor does not discriminate between a basic or a 
neutral amino acid at the position 8 of GnRH analogues (mGnRH : [Arg8]; cGnRH I : 
[Gln8]). On the other hand, cGnRH II [His5,Trp7, Tyr8] and [D-Arg6]cGnRH II exerted a 
IO-fold higher affinity than cGnRH I for the chicken receptor, as well as 63-, 126-fold 
potencies, respectively, on stimulating IP production. This confirms a previous study 
(Millar et al., 1989) that the substitutions of Trp7 and/or Tyr8 in GnRH analogues promote 
higher activity on LH release in the chicken pituitary. 
Conversely, mGnRH exhibited the highest potency (ED50: 20 pM) to stimulate IP 
production in COS-1 cells expressing the human GnRH-R, whereas cGnRH II and [D-
Arg6]cGnRH II showed an intermediate effect (ED50 : 0.3 - 0.5 nM), and cGnRH I was the 
least potent (EDso: 0.9 nM). These findings are concomitant with the results found in sheep 
and rat cultured pituitary cells on receptor binding and LH release (Millar et al., 1989), and 
in COS-1 cells transiently transfected with mouse GnRH-R cDNA (Flanagan et al., 1994) 
or transfected with human GnRH-R cDNA (Davidson et al. , 1996) on stimulating IP 
production. Taken together, the results demonstrate that the chicken receptor has a 
preference for GnRH analogues with substitutions of Trp7 and/or Tyr8; albeit less request 
for a basic or a neutral amino acids at position 8 in the analogues, while the mammalian 
receptor has a specific selection for the Arg8 of mGnRH. 
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It has been suggested from mutagenesis studies that the electrostatic interactions 
between the Arg8 residue of the ligand and the Glu301 residue of the mouse GnRH-R alter 
the receptor confonnation to a stable fonn, implying that the Glu301 of the receptor plays an 
important role in recognition of the Arg8 in the ligand (Flanagan et al., 1994). Interestingly, 
the Glu is also conserved in the chicken receptor (Glu293). However, the Glu in the chicken 
receptor does not preferentially favour the Arg8 of the ligand, since mGnRH and cGnRH I 
display an equal activity in receptor binding, stimulation of IP fonnation, and release ofLH 
(Millar et al., 1989). In addition, other postulated binding sites of mammalian GnRH-R, 
Lys121 and Asn102, are also conserved in the chicken receptor (as described above). Both 
residues Asn102 and Glu301 in the mammalian receptor display differential affinities to 
different GnRH agonists. For example, the mutant Ala102 of the human GnRH-R severely 
impaired ( over 200-fold decrease) its affmities to cGnRH I, cGnRH II and mGnRH, but 
only mildly affected ( only 20-fold decrease) its affinity to [D-Trp 6]GnRH by measuring 
those ligands in stimulating IP formation (Davidson et al., 1996). The mouse GnRH-R 
mutant, in which the Glu301 residue was mutated to Gin, exhibited a 56-fold decrease in 
apparent affinity for mGnRH, while its affinity for cGnRH II and cGnRH I was only 
decreased 2.2-fold and unchanged, respectively (Flanagan et al., 1994). The mutations at 
the putative binding sites of the mammalian receptor give rise to different effects on the 
binding affmity of GnRH agonists. This indicates that the binding sites of the mammalian 
GnRH-Rs for mGnRH might not be the same sites for other native GnRH analogues (i.e. 
cGnRH I and cGnRH II), perhaps overlapping. Thus, it is anticipated that the binding 
domains of the chicken receptor might share some similarity to those of the mammalian 
counterparts, however the chicken receptor is more susceptible to activation by GnRH 
analogues with substitutions ofTrp7 and/or Tyr8• 
An interesting question is: what factors might contribute to a receptor's preference 
(higher affmity) for a particular type of agonist? For example, the chicken receptor has 
higher affmity to cGnRH II analogues, whereas the mammalian homologue exhibits the 
highest affinity to mGnRH. This discrimination in both species might be due to the 
structural confonnation of the receptor required for receptor's activation. As discussed 
above, there are several different structural features in both receptors which may be 
attributed to receptor selectivity. In particular, the chicken receptor consists of the TM 2-
Asp and TM 7-Asp structural combination, instead of TM 2-Asn and TM 7-Asp in the 
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mammalian receptors. It has been postulated that an hydrogen-bonding network involving 
TM 2-Asp and TM 7-Asn forms a component of the helix:helix interactions which is 
required for the conformational change underlying receptor activation by agonists in the 5-
HT 2A receptor (Sealfon et al., 1995). Moreover, it was proposed that the TM 2-Asn and 
TM 7-Asp residues in the mammalian receptor play an important role in maintaining the 
normal receptor structure and receptor-G protein coupling (Zhou et al., 1994). In that 
study, the Asp87 mutant (Asp87 Asp318) abolished receptor binding for both agonist and 
antagonist, but the reciprocal mutant (Asp87 Asn318) restored high affinity binding for both 
ligands. However, the reciprocal mutant receptor showed poor coupling to the 
phosphoinositol turnover. The results are consistent with those found in the 5-HT2A 
reciprocal mutant receptor, whereas the TM 2-Asp/ TM 7-Asp mutant exhibits functions 
similar to the wild type receptor (Sealfon et al., 1995). The importance of the two residues 
in TM 2 and TM 7 for receptor activation was substantiated by another group (Blomenrohr 
et al., 1997, abstract). In the study, the TM 2-Asp and TM 7-Asp of the catfish receptor, 
whose C-terminal tail was truncated, were mutated into the TM 2-Asn/ TM 7-Asp, TM 2-
Asp/ TM 7-Asn, and TM 2-Asn/ TM 7-Asn combinations, respectively. Only the TM 2-
Asp/ TM 7-Asn mutant receptor responded to various GnRHs. 
Thus, the chicken receptor may represent a natural mutation, relative to mammalian 
receptor, so that unique structural configuration in the chicken receptor could occur due to 
the interaction network between these two residues and with other loci. The different 
conformation of the receptor might take a part in comprising a binding domain favoured by 
a higher-affinity agonist ( eg. cGnRH II) in the chicken receptor. The putative residues 
which account for this higher-affinity ligand in the chicken receptor remain to be identified. 
Agonistic behaviours of mammalian antagonists in the chicken GnRH-R 
The possibility of a different structural conformation between the chicken and 
mammalian receptors was suggested in pharmacological studies using mammalian GnRH 
antagonists. Of six selected mammalian GnRH antagonists, three antagonists display 
agonism in COS-I cells expressing the chicken GnRH-R. A135-18 acts as a full agonist 
and A135-25 and A26 display partial agonistic effects. The results are in accordance with 
the finding that A135-18 and A26 showed agonist activity in stimulating LH release from 
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chicken pituitary cells, but not from sheep pituitary cells (Jacobs et al. , 1995). This 
suggests that the opposite effect of those peptides is not caused by a different cell 
environment (COS-I cell or pituitary cell). Intriguingly, the structures of the antagonists 
reveal that D-Lys at position 6 is required for exerting partial agonist activity of these 
antagonists. If Lys is substituted with either Trp or Tyr (i.e. A27, Al34-46, and A134-53), 
the peptides inhibit cGnRH I-stimulated IP formation in COS-I cells expressing the 
chicken GnRH-R. Even replacing the Lys with Arg in the antagonists (i.e. A131-148 and 
Al31-146) results in inhibition of LH release in the chicken pituitary cells (Jacobs et al., 
i 995). These results suggest that a characteristic charge-strengthened hydrogen bond donor 
of Lys may account for the partial agonism, but the length of side chain might be crucial. It 
is of interest that the antagonist (i.e. Al35-18) which contains D-Lys at position six 
accompanied with Ile at the fifth position behaves as a full agonist. 
Little is known about the molecular mechanism of antagonists, while that of agonists 
has been studied extensively. In the two-state model of receptor activation (Samama et al., 
1993), it has been postulated that receptors are in equilibrium between the inactive 
conformation (R) and a spontaneously active conformation (R *) that can couple to G 
protein in the absence of ligand. Neutral competitive antagonists (pure antagonists) have 
equal affinity for R and R * and do not displace the equilibrium. However, agonists have a 
high affinity for R * and increase the concentration of R *. In this study, three antagonists 
exhibited a varying efficacy of agonism in the chicken receptor. To accommodate the 
findings in the two-state model, it was speculated that these antagonists might enhance a 
ligand-related constant (~) which represents the ability of hormone binding to overcome 
the receptor constrain (R), in order to drive the receptor into its active conformation which 
subsequently activated the G-protein (Samama et al. , 1993). The speculation is 
conceivable, because the agonism required the presence of ligand (i.e. antagonists), but 
how an antagonist binds to a receptor and generates "un-predicted" behaviour, that is a full 
or partial agonist effect. However, it lacks an explanation in the two-state model. 
The mechanism underlying the agonist effects by these antagonists in the chicken 
receptor remains elusive. There are two possible hypothesises to delineate the action. 
Firstly, the antagonists (A135-18, -25, and A26) do bind to the chicken receptor, according 
to competition binding and IP formation experiments. The results revealed that the binding 
domains of the antagonists may overlap with those of agonists, but might not be identical 
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as suggested by earlier reports (Zhou et al. , 1995; Strader et al. , 1988). After binding to the 
receptor, somehow, that hormone binding disrupted a mechanism constraining the receptor 
(Kjelsberg et al., 1992 ; Samama et al., 1993), which is absent or different from that of the 
mammalian receptor; then, promoted the receptor into a "relaxed" form that is optimal for 
G-protein activation. Interestingly, the C-terminal tail of the avian P-AR appears to be 
involved in the constraining effect in the native receptor (Parker and Ross, 1991 ). In the 
study, the P-AR which was truncated within the C-terminal tail, displayed 2- and 3-fold 
increase in the basal and exhibits partial agonist effect of two full antagonists. Moreover, 
the C-terminal tail of the mouse TRH-R is also involved in constraining the receptor in an 
inactive form (as indicated above) (Matus-Leibovitch et al. , 1995). Coincidentally, the 
chicken receptor contains a C-terminal tail, which is absent in the mammalian receptor. 
However, the mechanism of constraining receptor in the chicken is yet to be established. 
Rare expression of the chicken GnRH-R mRNA 
In this study, I did not succeed in isolating the chicken GnRH-R gene by screening 
cDNA libraries ( intact and castrated chicken pituitary libraries) using a mouse GnRH-R 
cDNA probe or the chicken GnRH-R genomic probe (which encodes a fragment from TM 
6 to TM 7 of the receptor). The implication is that the chicken GnRH-R mRNA is very low 
in abundance, and/or technical problems in the screening, or that the cDNA libraries are not 
satisfactory. However, three cDNA clones of the chicken TRH-R were isolated from the 
same screening membranes (see the "cTRH-R" section), suggesting that the libraries and 
technique applied in this study were satisfactory. Thus, the rare GnRH-R mRNA copy 
appears to account for the failure in the cloning work. There is other evidence to support 
this. According to the analysis of the Northern blot on the chicken pituitary gland, no 
positive results were obtained while the blot was hybridised with 32P-labelled chicken 
GnRH-R cDNA probe. In order to verify whether this result was due to a technical 
problem, the same blot membrane was re-hybridised with 32P-labelled chicken TRH-R 
cDNA probe. Three mRNA transcripts of the chicken TRH-R were identified (see the 
"TRH-R " section ), indicating that the failure of the Northern blot analysis can be 
attributed to extremely low copies of the chicken GnRH-R mRNA. Likewise, I was unab.le 
to trace a signal in the first-run nested PCR-products amplified from the castrated chicken 
pituitary cDNAs by means of Southern blot analysis. It appears that the chicken GnRH-R 
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mRNA is expressed at low levels even in the castrated condition, which has been suggested 
to up-regulate the receptor number (Illing et al. , 1993). 
As indicated above, PCR was the only successful strategy for isolating a full-length 
chicken GnRH-R cDNA. Three full-length chicken GnRH-:R cDNA clones (one clone was 
shown in the result section), were obtained by PCR. However, they comprised various 
amino acid sequence changes and at least 6 different "silent mutations" ( changed 
nucleotide sequence, but encoding the same amino acids), as compared to those of the 
chicken GnRH-R genomic clone. The three subclones all contained Arg (R) at position 
338 instead of the Glu (Q) in the genomic clone. Furthermore, the pCH6 subclone 
consisted of Lysine (K) at position 40 the same as the genomic sequence, while the pCH5 
and pCH7 (data not shown) subclones shared an identical sequence (Q) at that position. 
Even though they are all functional constructs, according to IP assay. It remains to be 
further investigated whether the variation of sequences are due to the polymorphism of the 






The mammalian TRH-R and GnRH-R have been cloned, and used to investigate 
their physiological roles in the physiological regulation of the hypothalamo-pituitary-
thyroid or hypothalamo-pituitary-gonad axis in mammals. However, there is little known 
about physiological functions of the receptors in the endocrinology of chickens, especially 
in growth and sexual maturation. The chicken TRH-R and GnRH-R were therefore cloned 
and characterised in this study. 
Understanding the molecular mechanism of ligand binding, signal propagation and 
G-protein coupling of the human GnRH-R, is crucial for rationally designing novel orally-
active analogues for application in reproductive medicine. Considerable progress in this 
regard has been made through a combination of computer modelling and mutagenesis 
studies. The sequence information from a related but pharmacologically distinct receptor 
would contribute substantially in these endeavours,. while the cloned mammalian receptors 
share over 85 % homology and exhibit similar ligand selectivity. 
The TRH-R and GnRH-R are well known as a rarely expressed receptor. Although 
the TRH-R and GnRH-R have been cloned from several mammalian species, their 
nucleotide sequence data might not be a useful tool to clone these receptors from chickens, 
because of being millions of years apart in evolution. In this study, a multiple combined 
strategy was used to clone both receptors from the chicken pituitary gland. It revealed that 
there were differential difficulties in cloning the two receptors. Although the TRH-R is 
more abundant than GnRH-R in the chicken pituitary, the truncated transcripts of TRH-R 
mRNA were highly expressed (related to the full-length transcript) in the pituitary gland. 
Only truncated forms of the chicken TRH-R cDNA were isolated from a cDNA library 
using the mouse TRH-R cDNA and a partial gene of the chicken TRH-R as probes. 
Therefore, there was a challenge to clone a full-length TRH-R. In order to isolate a 
functional TRH-R cDNA, multiple techniques (PCR, 3 'RACE, screening of a cDNA 
library) were applied in this regard. On the other hand, the chicken GnRH-R is 
extraordinarily rare in the pituitary gland and contains a strikingly low percentage of 
homology with the mammalian counterparts. The chicken GnRH-R cDNA cannot be 
cloned by screening cDNA libraries (the intact and castrated chicken pituitary gland) using 
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the mouse GnRH-R cDNA and a partial gene of the chicken GnRH-R as probes. A 
multiple combined strategy (including PCR, 5'-RACE, screening of a genomic library, 
nested PCR) was applied to clone a full-length chicken GnRH-R cDNA. 
The amino acid sequences of both receptors show that the chicken TRH-R and 
GnRH-R share about 84 % and 40 % identity to those of thier mammalian counterparts, 
respectively. Additionally, from pharmacological studies, the chicken GnRH-R displays a 
different selectivity for GnRH agonist analogues from that of the mammalian homologue 
and exhibits agonistic behaviours from the mammalian antagonists. On the other hand, 
there are no discriminatory properties on the receptor binding and IP formation between the 
chicken and mouse TRH-Rs. The findings suggest that there has been a functional demand 
for structural change in the mammalian GnRH-R during its evolution from the non-
mammalian ancestral receptor, whereas the TRH-R has considerable evolutionary 
constraints on both aspects for conserving functional importance, though several hundred 
millions of years of evolution. 
The chicken GnRH-R possesses several characteristically unique features and 
distinct pharmacological properties in its interaction with GnRH agonist and antagonist 
analogues. The comparative amino acid data between the chicken and mammalian GnRH-
Rs provides valuable information for recognising important elements in the receptors, 
which are involved in the structure and function. For example, our group has recently 
identified the EL 2 domain of the mammalian GnRH-R as a critical region for converting 
antagonism to agonism from one selected antagonist (i.e. antagonist 135-18). Moreover, we 
have shown that the chicken GnRH-R generate internalises 10-fold more rapidly than the 
human counterpart. Also, truncating the C-terminal tail of the chicken receptor at the S337 
residue changes the internalisation rate to that of the human receptor (Pawson et al., J. 
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